Document:

Exhibit

Exhibit 10.12
ACTION OF THE
ADMINISTRATIVE COMMITTEE OF THE FARMER BROS. CO.
QUALIFIED EMPLOYEE RETIREMENT PLANS

Farmer Bros. Co. Amended and Restated Employee Stock Ownership Plan

The undersigned members of the Administrative Committee, having the authority to act on the matter set forth below, hereby approve the following:

WHEREAS, Section 12.01 of the Farmer Bros. Co. Amended and Restated Employee Stock Ownership Plan (the “Plan”) permits amendments to the Plan from time to time.

WHEREAS, this Committee deems it appropriate to amend the Plan in certain respects as set forth below.

NOW, THEREFORE, BE IT RESOLVED, that the Plan is hereby amended effective as of January 1, 2012, as follows:

1. Section 1.11 is amended by changing the portion of the first sentence that precedes the comma to read as follows: “Compensation” means wages as defined under Section 3401(a) of the Code (for purposes of income tax withholding at the source) paid to a Member while he or she is an Eligible Employee, ....”

2. Section 2.03 is amended in its entirety to read as follows: “Notwithstanding any provision of the Plan to the contrary, a Member who transfers employment from the Employer to an Affiliate that is not participating in the Plan shall continue to be a Member for the Plan Year in which such transfer occurs but shall only be eligible to receive allocations of Employer Contributions with respect to Compensation.”

BE IT FURTHER RESOLVED, that the appropriate officers of the Company, and the individuals who have been properly delegated authority for the administration of the Plan, are hereby authorized to do such other things as may be necessary or advisable to give effect to the foregoing resolution.

Dated: August 8, 2012
	
		
	 

	 
	 

	

 /s/ Pat Quiggle
Title: Vice President of Human Resources
	

/s/ Hortensia Gomez
Title: Vice President, Controller

	

/s/ Jeffrey A. Wahba
Title: CFO
	

_____________________________________
Title: ________________________________EX-10.3

 Exhibit 10.3 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2 
  

							
		 	CONFIDENTIAL	 		 	            CorA: 151373

 GLOBAL SUPPLY AGREEMENT 

This Global Supply Agreement (the “AGREEMENT”), is made effective as of June 30, 2017 (the “EFFECTIVE
DATE”) by and between 
 Horizon Pharma Ireland Limited 

Connaught House 
 1 Burlington Road, Dublin 4 

Ireland 
     (hereinafter
referred to as “HORIZON”) 
 and 

Boehringer Ingelheim Biopharmaceuticals GmbH 
 Binger
Straße 173 
 55216 Ingelheim am Rhein 
 Germany 

(hereinafter referred to as “BI”), 

Hereinafter HORIZON and BI may be referred to herein each individually as a “Party” and jointly as the “Parties”. 

 

  
 Page 1 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 Table of Content 

					
			
	 1.
	 	INTRODUCTION AND RECITALS	  	3
			
	 2.
	 	DEFINITIONS	  	5
			
	 3.
	 	GENERAL	  	13
			
	 4.
	 	MANUFACTURE AND SUPPLY	  	16
			
	 5.
	 	PRICES AND PAYMENT	  	28
			
	 6.
	 	QUALITY ASSURANCE AND COMPLIANCE WITH LAW	  	29
			
	 7.
	 	CO OPERATION AND CO-ORDINATION BETWEEN THE PARTIES	  	33
			
	 8.
	 	INTELLECTUAL PROPERTY AND LICENSES	  	37
			
	 9.
	 	COMPLAINTS; ADVERSE EVENTS; RECALLS	  	38
			
	 10.
	 	REPRESENTATIONS AND WARRANTIES	  	39
			
	 11.
	 	INDEMNIFICATION	  	41
			
	 12.
	 	LIMITATIONS ON LIABILITY	  	42
			
	 13.
	 	CONFIDENTIALITY	  	42
			
	 14.
	 	DURATION AND TERMINATION	  	44
			
	 15.
	 	MISCELLANEOUS	  	48

  

  
 Page 2 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 1. INTRODUCTION AND RECITALS 

Whereas, InterMune, Inc. (“InterMune”) and Boehringer Ingelheim RCV GmbH & Co KG (“BI RCV”),
an AFFILIATE (as defined hereafter) of BI, entered into a previous supply agreement relating to the commercial supply of Actimmune® (as described below) dated 29 June, 2007
(“RESTATED SUPPLY AGREEMENT”) pursuant to the Termination Agreement dated 6 June 2007 (“TERMINATION AGREEMENT”) terminating the Data Transfer, Clinical Trial and Market Supply Agreement dated 27 January
2000, as amended (the “ORIGINAL SUPPLY AGREEMENT”); and 
 Whereas, Vidara Therapeutics Research Limited
(“VIDARA”) (now HORIZON, as described below) and BI RCV entered into a consolidated supply agreement effective as of 31 July 2013, as amended (the “CONSOLIDATED SUPPLY AGREEMENT”); and 

Whereas, the CONSOLIDATED SUPPLY AGREEMENT was assigned from BI RCV to its AFFILIATE BI, effective as of 1 January 2014, via an
assignment letter acknowledged by VIDARA on 13 December 2013; and 
 Whereas, Vidara Therapeutics International plc, the parent
company of VIDARA merged with Horizon Pharma Public Limited Company, an AFFILIATE of HORIZON, on 19 September 2014, and as of this date VIDARA was renamed and traded as HORIZON; and 

Whereas, HORIZON’s AFFILIATE Horizon Pharma Plc and BI entered into a technology transfer and development agreement, effective as
of 9 February 2015 (“LYOPHILISATION DEVELOPMENT AGREEMENT”) as [...***...] the CONSOLIDATED SUPPLY AGREEMENT; and 

Whereas, HORIZON terminated the LYOPHILISATION DEVELOPMENT AGREEMENT for convenience with termination letter of 15 September 2015
and effective as of 30 September 2016; and 
 Whereas, HORIZON is expected to become the exclusive licensee of and the holder of
an exclusive sublicense under a license from [...***...]; and 
 Whereas, BII (as defined hereafter) had originally obtained
exclusive licenses from GENENTECH to manufacture, use and sell INTERFERON GAMMA 1b in Europe and certain other territories under the trade-mark Imukin®, Immukin®, Imukine® and/or Immukine® (“BI- 

***Confidential Treatment Requested 

  
 Page 3 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 GENENTECH LICENSE AGREEMENTS”). BII and HORIZON’s AFFILIATE HZNP Limited entered into an
asset purchase agreement (“ASSET PURCHASE AGREEMENT”), effective as of May 18, 2016, as amended, under which HORIZON acquired all rights, title and interest from BII to INTERFERON GAMMA 1b, including the relevant confidential
information and trademarks, in the BII territory. 
 Whereas, in connection with the ASSET PURCHASE AGREEMENT, BII and HZNP Limited
anticipate that [...***...]. 
 Whereas, BII and HORIZON, in
connection with the ASSET PURCHASE AGREEMENT, entered into a Transition Service Agreement (“TRANSITION SERVICE AGREEMENT”) effective as of 30 June 2017, covering transitional services to be provided by BI and/or its AFFILIATES
until such time as HORIZON makes HORIZON-labelled PRODUCT available to patients; and 
 Whereas, BI and its AFFILIATES BI RCV and BI
Pharma KG (as defined hereinafter) own facilities specialised for cGMP manufacture of biopharmaceuticals and have been manufacturing and supplying the ACTIMMUNE PRODUCT (as defined hereafter) and IMUKIN PRODUCT (as defined hereafter) to BII and
HORIZON, as applicable; and 
 Whereas, HORIZON and BI agreed in amendment No. 2 to the CONSOLIDATED SUPPLY AGREEMENT with an
effective date of 1 June 2015 (“CSA AMENDMENT NO. 2”) to harmonise the current MANUFACTURING PROCESS (Exhibit 1a, 1b of CSA AMENDMENT NO. 2) for DRUG SUBSTANCE manufacture and the manufacturing process for PRODUCT manufacture
[...***...]; 
 Whereas, the Parties wish to enter into this GLOBAL SUPPLY AGREEMENT (“AGREEMENT”) to replace
the CONSOLIDATED SUPPLY AGREEMENT setting forth the terms and conditions pursuant to which BI will on a going forward basis manufacture and supply to HORIZON, and HORIZON will purchase from BI, DRUG SUBSTANCE and PRODUCT to meet HORIZON’s needs
with respect thereto. 
 Now, Therefore, in consideration of the foregoing recitals which are hereby incorporated by reference herein
and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: 

***Confidential Treatment Requested 

  
 Page 4 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 2. DEFINITIONS 

The following capitalized definitions will apply throughout this AGREEMENT: 

2.1 ACTIMMUNE PRODUCT means the liquid formulation of INTERFERON GAMMA 1b currently sold under the trademark Actimmune® and that is manufactured and supplied under this AGREEMENT by BI as further described in Exhibit 6.  

2.2 AFFILIATE means (i) any corporation or business entity fifty percent (50 %) or more of the voting stock of which is and continues to be owned
directly or indirectly by any party hereto; (ii) any corporation or business entity which directly or indirectly owns fifty percent (50 %) or more of the voting stock of any party hereto; or (iii) any corporation or business entity under
the direct or indirect control of such corporation or business entity as described in (i) or (ii). 
 2.3 AGREEMENT means this GLOBAL
SUPPLY AGREEMENT as set forth in the recitals above of this AGREEMENT.  
 2.4 APPROVAL means a regulatory approval required from a HEALTH
AUTHORITY in order to manufacture DRUG SUBSTANCE or PRODUCT for use in clinical trials or market supply as applicable, in the applicable jurisdiction. 

2.5 ASSET PURCHASE AGREEMENT has the meaning ascribed to it in the recitals above of this AGREEMENT. 

2.6 BACKGROUND IP means all INFORMATION and INTELLECTUAL PROPERTY RIGHTS (i) owned or CONTROLLED by a Party or any of its AFFILIATES as of the
EFFECTIVE DATE, or (ii) developed by a Party or any of its AFFILIATES or subcontractors during the term of this AGREEMENT independently and with no reference to the other Party’s CONFIDENTIAL INFORMATION and outside of the scope of this
AGREEMENT. 
 2.7 BATCH has the meaning as set forth in the QAA. 

2.8 BATCH RECORDS have the meaning as set forth in the QAA. 

2.9 BI BACKGROUND IP means all BACKGROUND IP owned or CONTROLLED by BI or any of its AFFILIATES as of the EFFECTIVE DATE which is used, applied or
otherwise employed by BI in the performance under this AGREEMENT. For the avoidance of doubt, BI BACKGROUND IP specifically excludes all INFORMATION and INTELLECTUAL PROPERTY RIGHTS included in the DIVESTED ASSETS, including the DRUG SUBSTANCE
MANUFACTURING PROCESS as described in Exhibit 7 (a and b). 
 2.10 BI-GENENTECH LICENSE AGREEMENTS has the same meaning as the “Genentech
Agreements” as defined in 1.1.(ii) of the ASSET PURCHASE AGREEMENT. 

  
 Page 5 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 2.11 BII means BI’s AFFILIATE Boehringer Ingelheim International GmbH, Binger Straße 173,
55216 Ingelheim am Rhein, Germany. 
 2.12 BI IMPROVEMENTS mean all IMPROVEMENTS that BI, its AFFILIATES or subcontractors discovers, develops,
conceives or reduces to practice under this AGREEMENT, individually or jointly among themselves, but excluding all HORIZON IMPROVEMENTS. BI IMPROVEMENTS include, but are not limited to, any such IMPROVEMENTS that are generally applicable to the
development and manufacture of biopharmaceutical products (i.e. applicable to at least one biopharmaceutical product other than INTERFERON GAMMA 1b). 

2.13 BI PHARMA KG means BI’s AFFILIATE Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Birkendorfer Straße
65, Germany, owning an FDA inspected and cGMP-certified facility.  
 2.14 BI RCV has the meaning ascribed to it in the recitals above of this
AGREEMENT. 
 2.15 BLA means HORIZON’s approved Biologics License Application for the PRODUCT in the United States of America. 

 2.16 BUSINESS CONTINUITY PLAN has the meaning as set forth in Section 4.8. 

2.17 cGMP means the current Good Manufacturing Practices of all applicable HEALTH AUTHORITIES, including without limitation the FDA (US) as set forth in
more detail in the QAA.  
 2.18 CHANGE OF CONTROL means, with respect to a particular Party, occurrence of any one or more of the following
events with respect to such Party: (i) the acquisition by any entity, that is not an Affiliate of such Party, of a majority of the total outstanding voting securities of the Party; (ii) the merger of such Party with a third party in a
transaction under which the holders of the outstanding voting shares of such Party, as of just prior to such merger, own less than fifty percent (50%) of the outstanding voting shares of the combined entity as of just after such event;
(iii) the acquisition by a third Party of beneficial ownership of more than fifty percent (50%) of the outstanding voting shares of such Party and/or all its Affiliates; or (iv) any sale (other than in the ordinary course of
business), exchange, transfer, acquisition or disposition, of all or substantially all of the assets of the Party relating to the PRODUCT (i.e., assets of the Party having a fair market value equal to more than eighty percent (80%) of the total
fair market value of all of the assets of the Party at such time) to an entity that is not an Affiliate of such Party.  
 2.19 CHANGE ORDER / CO
means a written document between the Parties setting forth the scope, objectives, deliverables, timelines, costs, fees and other details of each and any additional development work or additional commercial service(s) to be performed by BI under
this AGREEMENT, the agreed form of which shall be signed by the Parties. Each fully-executed CHANGE ORDER shall be incorporated by reference into this AGREEMENT. 

  
 Page 6 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 2.20 CMC means the Chemistry, Manufacturing, and Controls content of a submission to a HEALTH
AUTHORITY. 
 2.21 COA means a Certificate of Analysis, a document listing testing parameters, specifications and test results (in a format and
detail as listed in Exhibit 3) and as further set forth in the QAA. 
 2.22 COC means a Certificate of Compliance confirming compliance
with cGMP regulations and signed by BI RCV’s authorised Qualified Person, the Head of Production and the Head of Quality Assurance (in a format and such detail as listed in Exhibit 4) and as further set forth in the QAA. 

2.23 COMPONENTS means, collectively, all raw materials, consumables, resins, and equipment dedicated to the DELIVERED MATERIALS, and materials required
to process and package for shipment the DELIVERED MATERIALS in accordance with the DELIVERED MATERIAL SPECIFICATIONS.  
 2.24 CONFIDENTIAL
INFORMATION means any proprietary INFORMATION (a) disclosed by one Party to the other from and after the effective date of the ORIGINAL SUPPLY AGREEMENT (including, without limitation, disclosed in connection with the CONSOLIDATED SUPPLY
AGREEMENT), or (b) developed by either Party pursuant to this AGREEMENT, except in each case INFORMATION which (i) is already in the public domain at the time of its disclosure to the receiving Party; (ii) becomes part of the public
domain through no wrongful action or omission of the receiving Party after disclosure to the receiving Party; (iii) is already known to the receiving Party at the time of disclosure as evidenced by the receiving Party’s written records; or
(iv) is independently developed by the receiving Party without the use or application of the disclosing Party’s proprietary INFORMATION. For clarity, all Divested Confidential Information (as defined in the ASSET PURCHASE AGREEMENT) will
be deemed to be HORIZON’s CONFIDENTIAL INFORMATION, such that HORIZON will be deemed to be the disclosing Party, BI will be deemed to be the receiving Party, and subclause (b)(iii) above shall not apply with respect thereto.  

2.25 CONFORMING when used in reference to any DELIVERED MATERIAL means DELIVERED MATERIAL that has been manufactured in accordance with cGMP, the QAA
and DELIVERED MATERIAL SPECIFICATIONS. 
 2.26 CONSOLIDATED SUPPLY AGREEMENT has the meaning ascribed to it in the recitals above of this
AGREEMENT. 
 2.27 CONTROLLED means, with respect to any material, INFORMATION or INTELLECTUAL PROPERTY RIGHT possession of the ability by a
Party to grant access, a license, or a sublicense to such material, INFORMATION or INTELLECTUAL PROPERTY RIGHT as provided for herein (a) without violating an agreement with a Third Party and (b) without obligation to make any payments to
a Third Party as a result of such grant the other Party of such access, license or sublicense or the exercise thereof by such other Party unless such other 
  

  
 Page 7 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 Party has agreed in writing to reimburse the granting Party for such payments. The granting Party, at the
time such access, license or sublicense is required to be granted hereunder, will notify the other Party in writing of any payment obligation under subclause (b) above. 

2.28 CSA AMENDMENT NO. 2 has the meaning ascribed to it in the recitals above of this AGREEMENT.  

2.29 DELIVERED MATERIAL means EXCESS MATERIAL or PRODUCT, as applicable. 

2.30 DELIVERED MATERIAL SPECIFICATIONS means DRUG SUBSTANCE SPECIFICATIONS or PRODUCT SPECIFICATIONS, as applicable. 

2.31 DIVESTED ASSETS has the meaning ascribed in the ASSET PURCHASE AGREEMENT. 

2.32 DRUG SUBSTANCE means a bulk form of the PRODUCT. This bulk form is the
[...***...]. 
 2.33 DRUG SUBSTANCE MANUFACTURING PROCESS means the processes for
fermentation and purification of DRUG SUBSTANCE, as described in Exhibit 7 (a and b), which the Parties intend to replace with the process described in Exhibit 7(c) [...***...]. The DRUG SUBSTANCE MANUFACTURING PROCESS does
however not encompass the filling of the DRUG SUBSTANCE to PRODUCT, or the labelling and packaging of PRODUCT. 
 2.34 DRUG SUBSTANCE SPECIFICATIONS
mean all the specifications and tests, analytical methods and/or limits, and the results thereof, as applicable, for DRUG SUBSTANCE agreed to by the Parties and listed in Exhibit 2 and to which DRUG SUBSTANCE has to conform.  

2.35 EMA means the European Medicines Agency and any successor agency thereto. 

2.36 EQUIPMENT means all plant, columns, vessels, machines and in general all equipment of any kind used in the manufacture or storage of the DRUG
SUBSTANCE or the PRODUCT.  
 2.37 EURO means a euro, which is the European unit of currency.  

2.38 EXCESS MATERIAL means any excess DRUG SUBSTANCE from DRUG SUBSTANCE BATCHES manufactured by BI for the supply of PRODUCT to HORIZON to be
determined by BI after HORIZON’s annual commercial purchase obligations for each commercial year under the AGREEMENT have been met. 

***Confidential Treatment Requested 

  
 Page 8 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 2.39 FACILITY shall mean the biotech buildings and all other buildings located at Dr. Boehringer
Gasse 5-11, 1121 Vienna, Austria and at Birkendorfer Str. 65, 88397 Biberach, Germany and used by BI in the performance of BI’s obligations under this AGREEMENT.  

2.40 FDA means the United States Food and Drug Administration and any successor agency thereto. 

2.41 FD&C ACT means the United States Food, Drug & Cosmetic Act as amended from time to time and any supplements thereunder, and any
equivalent regulation of any HEALTH AUTHORITIES. 
 2.42 FINAL RELEASE means (a), with respect to PRODUCT, the release of PRODUCT by HORIZON or
its licensees for clinical trial use or market supply, as applicable, and (b) with respect to DRUG SUBSTANCE, the release of DRUG SUBSTANCE by HORIZON or its licensees. 

2.43 GENENTECH means Genentech, Inc. with its principal place of business at 1 DNA Way, South San Francisco, CA, 94080-4990, USA. 

 

	2.44	[...***...]. 

 2.45 HEALTH
AUTHORITIES mean all regulatory authorities having jurisdiction over the manufacture, use and/or sale of the PRODUCT in the TERRITORY, including but not limited to the FDA and the EMA. 

2.46 HORIZON BACKGROUND IP means all INFORMATION and BACKGROUND IP that was or is owned or CONTROLLED either by InterMune or HORIZON (or previously by
VIDARA) and required for the performance by BI of its obligations under this AGREEMENT. HORIZON BACKGROUND IP includes (a) all INFORMATION and INTELLECTUAL PROPERTY RIGHTS included in the DIVESTED ASSETS, and (b) all INFORMATION and
INTELLECTUAL PROPERTY RIGHTS relating to the manufacture, use or sale of INTERFERON GAMMA 1b [...***...], including without limitation the MANUFACTURING PROCESS as described in Exhibit 7 (a and b) and the PRODUCT MANUFACTURING PROCESS
as described Exhibit 16. 
 2.47 HORIZON IMPROVEMENTS mean all IMPROVEMENTS to HORIZON BACKGROUND IP relating specifically to the PRODUCT and /
or DRUG SUBSTANCE that BI, its AFFILIATES or subcontractors (whether solely or jointly with HORIZON, its AFFILIATES or subcontractors) discover, develop, conceive or reduce to practice under this AGREEMENT, but excluding any such IMPROVEMENTS that
are generally applicable to the development and manufacture of biopharmaceutical products (i.e. applicable to at least one biopharmaceutical product other than INTERFERON GAMMA 1b). Any IMPROVEMENTS of the DRUG SUBSTANCE MANUFACTURING PROCESS and/or
PRODUCT 
 ***Confidential Treatment Requested 

  
 Page 9 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 MANUFACTURING PROCESS shall be HORIZON IMPROVEMENTS only to the extent that they directly relate to the DRUG
SUBSTANCE and/or PRODUCT. 
 2.48 IMPROVEMENTS mean all INFORMATION and INTELLECTUAL PROPERTY RIGHTS, and all modifications, derivatives and
improvements of BACKGROUND IP or new uses thereof (whether or not protectable under patent, trademark, copyright or similar laws) that are discovered, developed, conceived or reduced to practice in the performance of this AGREEMENT.  

2.49 IMUKIN PRODUCT means the liquid formulation of INTERFERON GAMMA 1b, currently traded under the trademarks Imukin®, Immukin®, Imukine® and
Immukine®, [...***...] that is manufactured and supplied under this AGREEMENT by BI as further described in Exhibit 6.

 2.50 INFORMATION means (a) techniques, data, discoveries, inventions, practices, methods, knowledge, know-how, skill, experience, test data
(including pharmacological, toxicological and clinical test data), analytical and quality control data, regulatory submissions, correspondence and communications, marketing, pricing, distribution, cost, sales, manufacturing, patent, patent
applications and legal data or descriptions, compositions of matter, assays and biological materials, and (b) all INTELLECTUAL PROPERTY RIGHTS in and to any of the foregoing. 

2.51 INTELLECTUAL PROPERTY RIGHTS mean any and all now known or hereafter existing: (i) rights associated with works of authorship, including
copyrights and moral rights; (ii) trade secret rights; (iii) patent rights, including patent applications, and industrial property rights; (iv) other proprietary rights in all inventions (whether or not patentable), discoveries,
methods, processes, techniques, specifications, protocols, schematics, diagrams, reagents, compounds, samples, formulation, data, circuit designs, design layout, databases, data, and other forms of technology; and (v) all registrations,
applications, renewals, and extensions of the foregoing, in each case in any jurisdiction throughout the world, including, but not limited to, inventor’s certificates, utility models, substitutions, confirmations, reissues, re-examinations,
renewals or any like governmental grants for protection of inventions; and any pending application for any of the foregoing, including any continuation, divisional, substitution, additions, continuations-in-part, provisional and converted
provisional applications, as well as extensions and supplementary protection certificates based thereon. 
 2.52
INTERFERON-GAMMA l b means the recombinant human Interferon-Gamma 1b derived from [...***...]. The relevant amino acid sequence is set forth in Exhibit
5.  
  

	2.53	JOINT PROJECT TEAM means the team as described in Section 7.1. 

 ***Confidential
Treatment Requested 

  
 Page 10 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 2.54 LATENT DEFECT means, with respect to a Non-CONFORMING DELIVERED MATERIAL, that such
non-conformance hereof is not visible or easily detectable without any analysis in a laboratory. 
 2.55 MANUFACTURER’S RELEASE shall mean
BI’s release through its qualified person of a BATCH of DRUG SUBSTANCE or PRODUCT, conducted in accordance with the specified procedures and requirements defined in the QUALITY ASSURANCE AGREEMENT and applicable cGMP, which release signifies
that the BATCH meets the MANUFACTURER’S RELEASE (DRUG SUBSTANCE or PRODUCT, as applicable) SPECIFICATIONS. 
 2.56 MANUFACTURER’S RELEASE
SPECIFICATIONS shall mean the defined list of analytical test methods that BI is responsible for performing, and acceptance criteria for a PRODUCT and DRUG SUBSTANCE, as set forth in Exhibit 1 and Exhibit 2, as applicable, to all
of which a PRODUCT or DRUG SUBSTANCE must conform to in order to be considered acceptable for the disposition of the PRODUCT or DRUG SUBSTANCE for the intended use. Such MANUFACTURER’S RELEASE SPECIFICATIONS may be amended, supplemental or
otherwise modified by the Parties from time to time in accordance with the terms of this AGREEMENT and the QUALITY ASSURANCE AGREEMENT as applicable. 

2.57 MANUFACTURING PROCESS means the DRUG SUBSTANCE MANUFACTURING PROCESS or the PRODUCT MANUFACTURING PROCESS, as applicable.  

2.58 MASTER BATCH RECORD means controlled documents of BI, approved by authorized technical and quality representatives of BI, that provides written
instructions for the respective MANUFACTURING PROCESS and includes all relevant MANUFACTURING PROCESS parameters to be followed and Equipment and raw materials to be used.  

2.59 MATERIAL SUPPLY BREACH means a failure of BI: (a) to supply to HORIZON at
[...***...] of HORIZON’s binding forecasted requirements of DRUG SUBSTANCE or PRODUCT (or actual orders, if less) that are due for shipment by the designated shipment date during
the then-current calendar half-year; or (b) to repeatedly [...***...] materially violate against cGMP. 
 2.60 Non-CONFORMING means, with
respect to any DELIVERED MATERIAL, that such DELIVERED MATERIAL is not CONFORMING.  
 2.61 OBVIOUS DEFECT means, with respect to any
Non-CONFORMING DELIVERED MATERIAL, that such non-conformance is visible or easily detectable without any analysis in a laboratory. 
 2.62 ORIGINAL SUPPLY
AGREEMENT has the meaning ascribed to it in the recitals above of this AGREEMENT. 
 ***Confidential Treatment Requested

  
 Page 11 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 2.63 PRODUCT MANUFACTURING PROCESS means the processes for the filling of the DRUG SUBSTANCE to
PRODUCT, as well as the labelling and packaging of PRODUCT, as described in Exhibit 16. 
 2.64 PERMITTED SUBCONTRACTORS has the meaning as set
forth in Section 4.3.6.  
 2.65 PROCESS PACKAGE means the package, for the applicable MANUFACTURING PROCESS, containing the documentation
and materials set forth in Section 14.4.1 to the extent these documents and information are in existence as at the relevant transfer date and to the extent these are necessary and for the sole purpose that HORIZON or a secondary supplier may
implement the MANUFACTURING PROCESS and analytical methods in order to manufacture and produce DRUG SUBSTANCE and PRODUCT. 
 2.66 PRODUCT
means finished product(s) consisting of formulated INTERFERON GAMMA 1b as a [...***...] (the relevant amino acid sequence of the monomer is set forth in Exhibit 5) and
filled into the designated vials or other agreed containers (which may be labelled by BI for the U.S. and/or Canadian market only, or unlabelled, as set forth in the applicable rolling forecast) for clinical supply or for market supply, as described
in Exhibit 6, or alternatively shall mean finished product(s) of formulation buffer filled into the designated vials or other agreed containers for clinical supply (placebo). 

2.67 PRODUCT MANAGER means the responsible person designated by each Party to be responsible for the communication of all information concerning this
AGREEMENT. As of the EFFECTIVE DATE, the person designated as HORIZON’s PRODUCT MANAGER and the person designated as BI’s PRODUCT MANAGER are listed in Exhibit 8. Either Party may change its own designated PRODUCT MANAGER by
providing written notice thereof to the other Party.  
 2.68 PRODUCT SPECIFICATIONS mean all the specifications and tests, analytical methods
and/or limits, and the results thereof, as applicable, for the PRODUCT agreed by the Parties and set forth in Exhibit 1 within which the PRODUCT has to conform to be considered acceptable by HORIZON.  

2.69 PRODUCT TEAM means the team as listed in Exhibit 8 and described in Section 7.1. 

2.70 PROJECT LEADER meansthe responsible person designated by each PARTY to be responsible for the communication of all INFORMATION concerning this
AGREEMENT. Either Party may change its own designated PROJECT LEADER by providing written notice thereof to the other PARTY. 
 2.71 QUALITY ASSURANCE
AGREEMENT / QAA means that Quality Asurance Agreement effective April 26, 2016 between the Parties, as amended. 

***Confidential Treatment Requested 

  
 Page 12 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 2.72 RELEVANT YEAR shall mean (a) the calendar year in which the MANUFACTURER’S RELEASE of
the PRODUCT which caused the damage occurred, or (b) in case the damage is not caused by the use of PRODUCT, the calendar year when the damage occurred. 

2.73 RESIDUAL SHELF LIFE means, with respect to a vial of PRODUCT, the actual residual shelf life of such PRODUCT at the time of delivery to HORIZON
hereunder, which in no event shall be shorter than the residual shelf life set forth in Section 4.4.5. 
 2.74 RESTATED SUPPLY AGREEMENT has
the meaning ascribed to it in the recitals above of this AGREEMENT.  
 2.75 STEERING COMMITTEE means the committee as listed in Exhibit 8
and as further described in Section 7.4. 
 2.76 SOPs means standard operating procedures. 

2.77 TECHNOLOGY TRANSFER has the meaning as set forth in Section 14.4.1. 

2.78 TERMINATION AGREEMENT has the meaning ascribed to it in the recitals above of this AGREEMENT.  

2.79 TERRITORY means the countries set forth in Exhibit 12, as may be amended from time to time in accordance with Section 4.12. 

2.80 THIRD PARTY means any person other than the Parties and their respective AFFILIATES. 

2.81 TRANSFER SUPPORT has the meaning as set forth in Section 14.4.1. 

2.82 TRANSITION SERVICES AGREEMENT has the meaning ascribed to it in the recitals above of this AGREEMENT.  

2.83 US means the United States of America. 
 3.
GENERAL 
 3.1 HORIZON’s Tasks and Responsibilities 

3.1.1 Support 
 HORIZON shall timely send all
documentation, and otherwise timely provide all information and other assistance, reasonably requested by BI for use under this AGREEMENT. HORIZON shall provide such reasonable technical support at its own expense, which support shall include 

  
 Page 13 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 access to HORIZON’s expert personnel upon reasonable notice and at such reasonable times as the Parties
may agree. 
 3.1.2 Contact with Health Authorities 

3.1.2.1 HORIZON and its AFFILIATES shall have the overall responsibility regarding all contacts with the HEALTH AUTHORITIES with respect to the PRODUCT and
shall be solely responsible for filing all regulatory documents required by any HEALTH AUTHORITIES with respect to the PRODUCT, except as otherwise expressly set forth in the SDEA (as defined below), the TRANSITION SERVICES AGREEMENT or this
AGREEMENT. 
 3.1.2.2 Under Section 14.1 of the ASSET PURCHASE AGREEMENT, HORIZON’s AFFILIATE HZNP Limited and BI’s AFFILIATE BII agreed to
amend the Pharmacovigilance Agreement for Co-Marketing effective April 17, 2014 (the “SDEA”), which addresses the rights and obligations of the parties to the ASSET PURCHASE AGREEMENT in relation to global product safety. The
Parties agree that all questions regarding the monitoring of and reporting to HEALTH AUTHORITIES on global product safety of DRUG SUBSTANCE and/or PRODUCT are subject to the terms of the then-current SDEA. Once all the marketing authorizations have
been transferred to HZNP Limited, the Parties intend that the SDEA be amended to provide that HZNP Limited shall be solely responsible for the monitoring and reporting to HEALTH AUTHORITIES regarding the global product safety of the DRUG SUBSTANCE
and/or the PRODUCT. 
 3.1.2.3 BI shall support HORIZON in all matters regarding the manufacturing and quality control of DRUG SUBSTANCE and PRODUCT as
reasonably requested by HORIZON, but HORIZON shall be the leading party and thus be responsible for co-ordination of all regulatory matters. Notwithstanding the foregoing, as of the EFFECTIVE DATE and until
registration of HORIZON as manufacturing authorisation holder for IMUKIN PRODUCT in each of the countries listed in Exhibit 12 (TERRITORY) where a manufacturing authorization exists, BI shall be responsible for all contacts with the HEALTH
AUTHORITIES for IMUKIN PRODUCT in said country/countries in accordance with the terms of the TRANSITION SERVICES AGREEMENT. Following the registration of HORIZON as manufacturing authorisation holder for IMUKIN PRODUCT in a country, HORIZON shall be
responsible for all contacts with the HEALTH AUTHORITIES for IMUKIN PRODUCT in such country. 
 3.1.2.4 HORIZON will notify BI in due time, but in no event
later than [...***...] in advance of any meeting with any HEALTH AUTHORITIES with regard to manufacture, supply and quality control of the DRUG SUBSTANCE and/or PRODUCT manufactured
by BI under this AGREEMENT. BI shall have the right to participate in such meetings with such HEALTH AUTHORITIES during the portion of such meetings relating to BI’s manufacture, supply and quality control of the DRUG SUBSTANCE and/or PRODUCT.

 3.1.2.5 BI will be responsible for drawing up the annual report required by the HEALTH AUTHORITIES reasonably in advance of the due date, and will be
responsible of matters 
 ***Confidential Treatment Requested 

  
 Page 14 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 regarding the manufacture of PRODUCT. HORIZON shall submit such report to the HEALTH AUTHORITIES and shall
provide BI with a copy of the finally submitted report. 
 3.1.3 Shipment of Material by HORIZON 

Any materials, e.g. samples, sent by HORIZON (or by a Third Party on behalf of HORIZON) to BI under this AGREEMENT shall be made by shipment from
HORIZON’s facility (or the Third Party’s facility, as the case may be) to BI shall be made [*...***...] to the FACILITY in Vienna. Thus, shipping costs including insurance
will be borne by HORIZON, and risk of loss in transit shall lie with HORIZON. Along with each shipment, HORIZON shall provide to BI, as applicable, shipping documents indicating [...***...]. 

3.2 BI’s Tasks and Responsibilities 
 3.2.1
Regulatory Support 
 3.2.1.1 BI agrees to co-operate with HORIZON in obtaining and maintaining all governmental approvals and registrations in the
TERRITORY relevant to the chemistry, manufacturing and control (“CMC”) section of the registration dossier (and their foreign equivalents) for the PRODUCT as requested by HORIZON. 

3.2.1.2 The Parties shall consult with each other concerning the scope and content of all regulatory filings pertinent to BI’s responsibilities for
manufacture and supply of PRODUCT, and shall jointly define the requirements for the necessary PRODUCT registration with the applicable HEALTH AUTHORITIES so that BI shall be able to fulfill its obligations under this AGREEMENT with respect to the
CMC portion of such PRODUCT registration. With respect to any part of the CMC portion which contains INFORMATION of BI and/or its AFFILIATES, BI shall be provided an opportunity of twenty (20) business days in accordance with Section 14.1.5 of
the QAA, or such other period as the Parties may agree in writing (the “REVIEW PERIOD”), to review and approve in writing the CMC section(s) of any regulatory filing which contain any data generated by BI relating to the manufacture and
testing of the Product at BI and / or the facility prior to submission of such filing by HORIZON to a HEALTH AUTHORITY, which approval shall not be unreasonably withheld, conditioned or delayed. If BI does not notify HORIZON in writing of any
material objection to any CMC section(s) provided to BI in accordance with the preceding sentence within the REVIEW PERIOD, then BI shall be deemed to have approved such CMC section for provision to the applicable HEALTH AUTHORITIES. The foregoing
BI review and prior approval shall not apply and a notification by HORIZON to BI shall be sufficient in the event that documents issued by BI for regulatory purposes are provided to any such Governmental Authority without further processing or
changes by HORIZON. The Parties shall agree in good faith on the required time periods for such review and approval and for any compilation, review and approval of regulatory documents in general in the Quality Agreement or otherwise in writing.

 ***Confidential Treatment Requested 

  
 Page 15 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 3.2.2 Format and Content of Documents 

BI’s Quality Management System demands a special format for certain documents (i.e. BATCH RECORDS, testing procedures, technical reports) which is
binding. For those documents where a binding format is not obligatory, the Parties shall agree in writing on a master format. With respect to the dates contained in these documents, and in particular in all reports and when dates occur in connection
with signatures, the European writing style shall apply. The order shall be as follows: dd / mm / yy (day/month/year). 
 3.3 Harmonised MANUFACTURING
PROCESS 
 The Parties understand that BI’s manufacturing and supply obligations hereunder are dependent on [...***...]. In the event that [...***...]. 
 4. MANUFACTURE
AND SUPPLY 
 4.1 Continuing Services from CONSOLIDATED SUPPLY AGREEMENT/CSA AMENDMENT NO. 2; Use of DRUG SUBSTANCE

 The Parties agree that BI shall continue to conduct under this AGREEMENT the services agreed pursuant to CSA AMENDMENT NO. 2 and adapted in agreement
between the PARTIES as set forth in Exhibit 17. 
 The DRUG SUBSTANCE and PRODUCT manufactured from the Process and Performance Qualification
(PPQ) activities shall, [...***...], be used to provide HORIZON’s commercial requirements of PRODUCT in the TERRITORY for the commercial years [...***...], and the Parties acknowledge that such PRODUCT from PPQ fill and finish
Batches will be paid for as per the billing plan of Exhibit 9. BI shall perform additional fill and finish runs using DRUG SUBSTANCE manufactured under the harmonization program and HORIZON shall pay for the fill and finish services only, as
set forth in Exhibit 10. 
 4.2 Scope Changes and Change Orders 

4.2.1 In case HORIZON requests additional services beyond those described in Section 3 or Section 4.1, including but not limited to additional
regulatory support, or extension of the scope of services or BATCHES, the Parties shall negotiate in good faith the detailed scope, timelines 

***Confidential Treatment Requested 

  
 Page 16 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 and prices of such service. Upon HORIZON’s request BI shall prepare a proposal specifying the required
services. Any agreed service shall be set forth in writing in the form of a CHANGE ORDER. Once a CHANGE ORDER is executed, such services or BATCH identified therein shall be subject to the terms and conditions of this AGREEMENT. 

4.2.2 For clarity, HORIZON may request DRUG SUBSTANCE supply from BI under mutually acceptable terms, including but not limited to price, forecasting and
minimum purchase order.. HORIZON acknowledges that BI requires a minimum of [...***...] prior notice to schedule additional BATCHES of DRUG SUBSTANCE, and BI agrees that it will
manufacture such BATCHES within this time frame, under the condition that the Parties agree on the the mutually acceptable terms for such BATCHES. The Parties shall negotiate in good faith such price and any other necessary terms for manufacture and
shipment of additional BATCHES of DRUG SUBSTANCE. 
 4.3 General Provisions for the Services 

4.3.1 BI shall exclusively (i) manufacture and supply to HORIZON EXCESS MATERIAL in bulk form and (ii) subject to Section 4.3.2, manufacture and
supply to HORIZON PRODUCT [...***...], using DRUG SUBSTANCE produced by BI or provided by HORIZON, to HORIZON. BI shall not supply DRUG SUBSTANCE or PRODUCT [...***...]. However, provided that HORIZON’s rolling forecast according to
Section 4.4 can be satisfied by BI, HORIZON shall not unreasonably withhold, delay or condition any request of BI or its AFFILIATES to use any PRODUCT to satisfy any of their own commitments towards HEALTH AUTHORITIES or other branches of
governments located in jursidictions that are not subject to the terms of the ASSET PURCHASE AGREEMENT. If BI manufactures and supplies PRODUCT using DRUG SUBSTANCE provided by HORIZON or that HORIZON has purchased separately from BI
[...***...]. 
 4.3.2 HORIZON shall exclusively purchase from BI [...***...] of HORIZON’s clinical trial supply and its market requirements
for PRODUCT for the term of this AGREEMENT, subject to Section 4.9 (Continuity of Supply). In addition, subject to a minimum of [...***...] prior notice and the Parties reaching written agreement on all matters set forth in
Section 4.2.2, HORIZON shall exclusively purchase from BI [...***...] of HORIZON’s requirements for DRUG SUBSTANCE for the term of this AGREEMENT, subject to Section 4.9 (Continuity of Supply). For clarity, the exclusivity
obligation in this Section 4.3.2 shall not apply to [...***...]. 
 4.3.3 All DRUG SUBSTANCE and PRODUCT manufactured for and/or supplied to
HORIZON by BI hereunder shall be manufactured at the FACILITY in accordance with the DRUG SUBSTANCE SPECIFICATIONS and PRODUCT SPECIFICATIONS, respectively, the 

***Confidential Treatment Requested 

  
 Page 17 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 cGMP requirements, the QUALITY ASSURANCE AGREEMENT and all applicable laws, regulations and ordinances
in the jurisdictions in which such manufacture occurs. Provided that HORIZON is able to provide to BI storage and temperature log documentation showing that the DRUG SUBSTANCE or PRODUCT, as applicable, delivered to HORIZON has been stored under
approprate conditions, BI warrants (gewährleistet) that such PRODUCT shall meet the applicable stability specifications until the end of the residual shelf-life. lt is understood that HORIZON is responsible for the compliance with
applicable laws of the regulatory filings of the PRODUCT, and that changes and/or variations to the DRUG SUBSTANCE SPECIFICATIONS and/or PRODUCT SPECIFICATIONS affecting the BLA or other regulatory submissions to the BLA or any marketing
authorization in the TERRITORY shall be initiated by Horizon in accordance with the QUALITY ASSURANCE AGREEMENT and the TRANSITION SERVICE AGREEMENT; provided that BI shall promptly inform HORIZON in writing if updates are needed to the CMC sections
of any regulatory submissions for the DRUG SUBSTANCE or PRODUCT if it is an update that has been requested by a HEALTH AUTHORITY or HORIZON, or if BI becomes aware of an issue that would have impact on the registration for the DRUG SUBSTANCE or
PRODUCT (for example, as the result of a routine inspection and deficiency noted that needs to be improved).  
 4.3.4 The Parties agree that that the
minimum campaign length is [...***...] of PRODUCT and thus that BI will not offer any [...***...] campaigns. 

4.3.5 Supply of Excess Drug Substance 
 In
the event of any EXCESS MATERIAL being available, HORIZON may purchase under a CHANGE ORDER order from BI such EXCESS MATERIAL, to be supplied in accordance with the price set forth in Exhibit 10. For clarity, EXCESS MATERIAL produced
pursuant to CSA AMENDMENT NO. 2 shall be used for development or clinical activities, including but not limited to new PRODUCT applications, or as otherwise permitted under the respective CHANGE ORDER, and the prices set forth in Exhibit 10
shall apply to such EXCESS MATERIAL. The terms and conditions of this AGREEMENT relevant for each supply of EXCESS MATERIAL shall apply hereto. Further, and in accordance with Section 10.7.1.1, HORIZON will in no event use any expired EXCESS
MATERIAL in humans.  
 4.3.6 Subcontracting 

Rights and obligations under this AGREEMENT may not be subcontracted by BI in whole or in part without the prior written consent of HORIZON. Notwithstanding
the foregoing, HORIZON herewith gives express consent that BI may subcontract the services under this AGREEMENT in whole or in part to (a) its AFFILIATE BI RCV, (b) its AFFILIATE BI Pharma KG and (c) those subcontractors set forth in
Exhibit 13 (the entities described in subclauses (a), (b) and (c) above, and any other subcontractor for which HORIZON gives its consent as set forth in this Section 4.3.6, collectively referred to as “PERMITTED
SUBCONTRACTORS”). Notwithstanding the foregoing, no PERMITTED SUBCONTRACTOR shall perform any manufacturing activity under this AGREEMENT for which such PERMITTED SUBCONTRACTOR’s manufacturing facilities would be required to comply with
cGMP under applicable laws unless and until BI and 
 ***Confidential Treatment Requested 

  
 Page 18 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 HORIZON have entered into a written agreement with respect to ensuring such PERMITTED SUBCONTRACTOR’s
compliance with cGMP. 
 BI shall be responsible and liable for all activities (including omissions) of any PERMITTED SUBCONTRACTORS in connection with this
AGREEMENT as if such activities or omissions were performed or made by BI. BI shall ensure that any PERMITTED SUBCONTRACTORS shall be bound by written agreements consistent with this AGREEMENT and QUALITY ASSURANCE AGREEMENT and containing:
(a) confidentiality obligations no less restrictive than those in this AGREEMENT and (b) provisions that are sufficient to enable BI to grant INTELLECTUAL PROPERTY RIGHTS granted to HORIZON under this AGREEMENT. 

4.4 Forecasts 
 HORIZON shall provide a rolling forecast
for [...***...] for PRODUCT in the format set forth in Exhibit 11. For clarity, [...***...]. 
 4.4.1 [...***...].
From the EFFECTIVE DATE until [...***...] and the manufacturing process for PRODUCT (Exhibit 16), HORIZON agrees to order the PRODUCT in filling lot quantities or multiples thereof (available lot sizes as of the EFFECTIVE DATE are
[...***...] vials, as follows: [...***...] of ACTIMMUNE PRODUCT and [...***...] of IMUKIN PRODUCT per [...***...].  

4.4.2 [...***...]. After [...***...] and the PRODUCT MANUFACTURING PROCESS (Exhibit 16) with the FDA, HORIZON agrees to order
the PRODUCT in filling lot quantities or multiples thereof of [...***...] vials. HORIZON shall be obligated to purchase amounts of PRODUCT in full lot size of [...***...] vials, under this AGREEMENT consistent with the binding/nonbinding
rolling forecast set forth in Section 4.4 above. At minimum, HORIZON shall order [...***...] vials of PRODUCT per calendar year (prorated for partial calendar years). If HORIZON requires more PRODUCT than set forth in the current firm
forecast, BI shall use commercially reasonable efforts in good faith to supply HORIZON with PRODUCT as requested; provided that for the amounts of PRODUCT in excess of such forecast which BI is unable to supply, despite such commercially
reasonable 
 ***Confidential Treatment Requested 

  
 Page 19 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 efforts, HORIZON may use a secondary source manufacturer for PRODUCT in accordance with the procedures set
forth in Section 4.9. 
 4.4.3 If HORIZON reduces the forecast for [...***...], then HORIZON shall be obligated to pay for PRODUCT which was not
ordered [...***...]. Similarly, if HORIZON reduces the forecast [...***...], then HORIZON shall be obligated to pay for PRODUCT which was not ordered [...***...] [...***...]. BI shall mitigate HORIZON’s payment
obligations under this Section 4.4.3 by allocating any available capacity resulting from HORIZON’s reduction of the forecast to a BI AFFILIATE or a THIRD PARTY. 

4.4.4 BI shall guarantee that at the date of MANUFACTURER’S RELEASE all DELIVERED MATERIAL supplied to HORIZON shall have a minimum RESIDUAL SHELF LIFE of
not less than [...***...] based on an approved shelf life of [...***...], provided that HORIZON shall strictly fulfill its contractual timelines regarding FINAL RELEASE as set forth in Sections 4.7 and 5. 

4.4.5 Subject to Section 4.6, BI shall ship all EXCESS MATERIAL and/or PRODUCT by the date and in the quantities specified in the applicable purchase
order. BI shall be obligated to accept any purchase order within the range of permitted variation in the forecasted quantities as set forth in Section 4.4.1 and 4.4.2. If BI does not accept such a purchase order with respect to PRODUCT, then
HORIZON may use a secondary source manufacturer for such PRODUCT in accordance with the procedures set forth in Section 4.10. Any other purchase order shall be binding on BI only if it is accepted by BI, which acceptance shall not be
unreasonably withheld. 
 4.4.6 HORIZON shall be obligated to buy and BI shall be obligated to sell only the quantities of EXCESS MATERIAL and/or PRODUCT
which are subject to a purchase order accepted by BI; provided that BI shall accept sufficient purchase orders from HORIZON annually to meet its obligations pursuant to this Section 4.4 and in accordance with the rolling forecast model pursuant
to Section 4.4. Any purchase order (or portion thereof) for which HORIZON has not received a written rejection from BI within [...***...] of BI’s receipt of such purchase order shall be deemed accepted by BI. With respect to PRODUCTS
ordered by HORIZON for its clinical supply requirements, the number of vials supplied by BI shall not exceed the number of vials subject to the applicable purchase order submitted by HORIZON; provided, however, that if the number of vials BI is able
to supply falls below the number of vials ordered by HORIZON in such purchase order and such lesser number is within a reasonable range of the number ordered by HORIZON, BI shall notify HORIZON in writing and inquire as to whether such lesser number
of vials is acceptable and if not, whether BI should produce an additional BATCH of DRUG SUBSTANCE to produce enough vials to satisfy HORIZON’s purchase order. If HORIZON notifies BI that such lesser number of vials is acceptable to HORIZON,
then the applicable purchase order shall be deemed to be amended to 
 ***Confidential Treatment Requested 

  
 Page 20 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 4.4.7 provide for such lesser number of vials and BI shall be deemed to have accepted such purchase order in
accordance with Section 4.4 and 4.5 (and HORIZON shall only be required to pay for the number of vials actually delivered). On the other hand, if HORIZON notifies BI that BI should manufacture an additional BATCH of DRUG SUBSTANCE to produce
the number of vials ordered by HORIZON in its purchase order submitted to BI, then BI shall be obligated to produce the additional BATCH of DRUG SUBSTANCE, HORIZON shall be obligated to purchase any excess vials (above the amounts forecasted in
accordance with Section 4.4) of PRODUCT from such additional BATCH of DRUG SUBSTANCE and the purchase order submitted to BI by HORIZON shall be deemed amended to account for any excess vials resulting from the additional BATCH of DRUG SUBSTANCE
and such purchase order shall be deemed accepted by BI in accordance with Section 4.4 and 4.5. In the event HORIZON prefers to purchase any EXCESS MATERIAL of said additional BATCH, Section 4.3.5 shall apply. 

4.4.8 For the avoidance of doubt, HORIZON shall supply separate forecasts and purchase orders according to Exhibits 10 and 11 in
accordance with Sections 4.4 and 4.5.  
 4.4.9 For the sake of clarity, Section 4.4 sets forth HORIZON’s purchase obligations, whereas the
purchase orders set forth in Section 4.5 serve financial transactional purposes only. Thus, in the unlikely event of a contradiction between Section 4.4 (Forecasts) and 4.5 (Purchase Orders) regarding HORIZON’s purchase obligations,
Section 4.4 shall prevail. 
 4.5 Purchase Orders 

4.5.1 For financial transaction purposes and to document the agreed shipment date when purchasing PRODUCT or EXCESS MATERIAL hereunder, HORIZON shall submit
written purchase orders to BI in accordance with the binding forecast as set forth under Section 4.4 above. The Parties acknowledge that due to the internal guidelines, procedures or systems of a Party it might not be avoidable that
communication or documents and the like are issued containing a reference to the general terms and conditions of such Party. Moreover, each Party acknowledges that the other Party for such reasons as outlined in the previous sentence might not be
able to avoid the issuance of one or more purchase orders or acceptance documents (or the like) replicating what was already agreed upon in this AGREEMENT and which due to technical reasons of the system might contain a reference to such other
Party’s general terms and conditions. Therefore, the Parties agree that the general terms and conditions of the Parties shall not apply, even if reference is made thereto in such purchase order (or the like) or any other communication or
documents related to this AGREEMENT. 
 4.5.2 Purchase orders shall include (i) the ordered quantity of PRODUCT and/or EXCESS MATERIAL, as applicable,
(ii) the agreed shipment date(s), (iii) the price, (iv) the designation of HORIZON’s carrier; and (v) any other information dictated by the circumstances of the order. 

4.6 Shipment of Product and Material by BI 
 4.6.1
DELIVERED MATERIAL and all material (e.g. samples) shall be shipped [...***...] at the FACILITY and shipped to HORIZON or as directed by HORIZON, in accordance 

***Confidential Treatment Requested 

  
 Page 21 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 with [...***...] and in accordance with the QUALITY ASSURANCE AGREEMENT. HORIZON’s designated
carrier shall be used to ship DELIVERED MATERIAL to the site designated by HORIZON. BI shall use commercially reasonable efforts to notify HORIZON in writing upon loading of the DELIVERED MATERIAL onto such designated carrier. The Parties
acknowledge and agree that [...***...] shall be responsible and bear the cost [...***...] the DELIVERED MATERIAL onto the [...***...] carrier such that [...***...] onto the HORIZON designated carrier. Risk of loss in transit
by [...***...]. 
 4.6.2 BI will provide or will have provided assistance to HORIZON regarding necessary procedures for exportation and/or importation
of DELIVERED MATERIAL. 
 4.7 Testing and Rejection 

4.7.1 HORIZON shall as soon as reasonable practicable and in any case within [...***...] (solely with respect to OBVIOUS DEFECTS that are readily
apparent upon visual inspection) or [...***...] (for all other OBVIOUS DEFECTS), from the date of physical receipt of DELIVERED MATERIAL delivered to HORIZON hereunder, reject such delivery (in whole or in part) in the event that it is
Non-CONFORMING due to an OBVIOUS DEFECT by written notice thereof to BI, indicating the relevant BATCH description and HORIZON’s reasons for rejection. If HORIZON fails to notify BI within said [...***...] time period, HORIZON shall be
deemed to have accepted such delivery and HORIZON shall not be entitled to any remedies for such OBVIOUS DEFECTS under this AGREEMENT, including but not limited to this Section 4.7 and 11. Notwithstanding the foregoing, HORIZON shall have the
right to revoke its acceptance of such DELIVERED MATERIAL if it later discovers LATENT DEFECTS not reasonably discoverable at the time of receipt, and retains all rights and remedies hereunder with respect to such LATENT DEFECTS, subject to the time
limitations set forth in Section 4.7.3. 
 4.7.2 HORIZON shall have [...***...] from the date of discovery that the DELIVERED MATERIAL is
Non-CONFORMING owing to a LATENT DEFECT, to reject such DELIVERED MATERIAL (in whole or in part) by written notice thereof to BI, indicating the relevant BATCH description and HORIZON’s reasons for rejection. If HORIZON fails to so notify BI
within said [...***...] time period, HORIZON shall be deemed to have accepted such delivery of DELIVERED MATERIAL and HORIZON shall not be entitled to any remedies for such LATENT DEFECT under this under this AGREEMENT, including but not
limited to this Section 4.7 and Section 11. 
 4.7.3 Notwithstanding the above, any and all remedies for Non-CONFORMING PRODUCT pursuant to this
Section 4.7 shall be time-barred following expiration of the RESIDUAL SHELF LIFE of such PRODUCT. BI’s warranties under Section 4.3.3 with respect to such PRODUCT shall expire upon expiration of the RESIDUAL SHELF LIFE of such 

***Confidential Treatment Requested 

  
 Page 22 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 PRODUCT, and BI shall have no liability under Section 11.1 with respect any product liability due to the
use of any PRODUCT following the expiration of its RESIDUAL SHELF LIFE. 
 4.7.4 If BI receives a notice from HORIZON pursuant to Section 4.7.1 or 4.7.2
that HORIZON does not accept any DELIVERED MATERIAL supplied hereunder, then BI shall immediately start re-testing the DELIVERED MATERIAL using the retained samples in order to evaluate process issues and
other reasons for such non-compliance. 
  

	4.7.5	If BI does not accept HORIZON ́s assertion that the rejected DELIVERED MATERIAL is Non-CONFORMING: 

(i) BI will provide written notice to HORIZON that the rejection is not accepted stating in detail the reasons for BI’s assertion
that the DELIVERED MATERIAL is CONFORMING. Such written notice by BI shall be provided to HORIZON within [...***...] after receipt of HORIZON’s notice of rejection pursuant to
Section 4.7.1 or 4.7.2; and 
 (ii) both Parties will try to find a mutually acceptable solution through referral to the STEERING
COMMITTEE in accordance with Section 7.2. If the STEERING COMMITTEE fails to find a mutually acceptable solution within [...***...] after HORIZON’s receipt of BI’s notice under sub-Section 4.7.5(i) above, then: 

(iii) HORIZON shall immediately provide a representative sample of the DELIVERED MATERIAL from the relevant shipment received by HORIZON
and/or related documentation to a mutually agreed upon, independent THIRD PARTY who shall be responsible for determining whether the relevant DELIVERED MATERIAL rejected by HORIZON is CONFORMING or Non-CONFORMING; and 

(iv) BI shall immediately provide to such mutually agreed upon, independent Third Party a representative sample of DELIVERED MATERIAL
from the relevant shipment delivered to HORIZON and/or all documentation relating to the manufacture of the relevant DELIVERED MATERIAL that the independent THIRD PARTY deems necessary to fulfil its obligations. 

Both Parties shall be bound by the determination of such independent THIRD PARTY (such determination to be made in accordance with the timelines as set forth
in the investigation plan) which determination shall be made in writing and shall include reasoning, and the Party against which the determination is made shall bear all costs associated with such THIRD PARTY determination, including those of the
Party in whose favour the THIRD PARTY determination is given. The independent THIRD PARTY shall be required to enter into written undertakings of confidentiality and non-use with respect to CONFIDENTIAL INFORMATION no less burdensome than those set
forth in this AGREEMENT. 
 4.7.6 Whether or not BI accepts HORIZON ́s assertion that the DELIVERED MATERIAL rejected by HORIZON in accordance with
Section 4.7.1 or 4.7.2 is Non-CONFORMING and 
 ***Confidential Treatment Requested 

  
 Page 23 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 irrespective of the independent THIRD PARTY determination referred to in Section 4.7.5, BI shall, upon
receipt of the notice of rejection, consult with HORIZON and use commercially reasonable efforts, as soon as reasonably practicable as mutually agreed by the Parties, to (i) provide a replacement shipment for the DELIVERED MATERIAL rejected by
HORIZON, (ii) rework or reprocess (solely to the extent permitted under, and in accordance with, the QUALITY ASSURANCE AGREEMENT) the Non-CONFORMING DELIVERED MATERIAL in accordance with the Parties’ quality system procedures and the
Parties’ mutual agreement thereto and deliver such reworked or reprocessed DELIVERED MATERIAL to HORIZON (which shall remain subject to the RESIDUAL SHELF LIFE provisions of Section 4.4.4) or (iii) issue a credit note for any payments
made by HORIZON for the Non-CONFORMING DELIVERED MATERIAL. 
 4.7.7 If any DELIVERED MATERIAL rejected by HORIZON in accordance with Section 4.7.1 or
4.7.2 is ultimately determined to be Non-CONFORMING or BI accepts that the DELIVERED MATERIAL is Non-CONFORMING, BI shall bear all expenses (including raw materials) for any manufacture and shipment of replacement or reworked/reprocessed DELIVERED
MATERIAL, provided that the replacement cost for a vial of a cell line shall be and not exceed [...***...] (with any costs in excess being at HORIZON’s expense). In addition, BI
shall make arrangements for the return or disposal, at BI’s sole discretion, of the Non-CONFORMING DELIVERED MATERIAL, provided, however, that in the case of PRODUCT that has been distributed (whether commercially or for clinical trials), such
PRODUCT shall be subject to Section 9.2. BI shall pay or reimburse HORIZON for any reasonable return shipping charges or out-of-pocket costs incurred by HORIZON for any return shipment or lawful disposal of such Non-CONFORMING DELIVERED
MATERIAL in accordance with BI’s reasonable instructions. 
 4.7.8 If any Product rejected by HORIZON pursuant to Section 4.7.1 or 4.7.2 is
ultimately determined to be CONFORMING, HORIZON shall either make payment to BI in accordance with Section 5 not only for the prices relating to the original shipment of the relevant PRODUCT now determined to be CONFORMING, but also for the
prices relating to the replacement shipment of Product, or BI shall balance out the credit note issued pursuant to Section 4.7.6. 
 4.7.9 In addition
to the provisions relating to the same set out in this AGREEMENT, acceptance and rejection, inspection and testing of DELIVERED MATERIAL shall be subject to each Parties’ rights and obligations as set out in the QAA. 

4.7.10 If BI becomes aware that any shipment of PRODUCT to HORIZON is Non-CONFORMING, BI will promptly notify HORIZON in accordance with the QUALITY ASSURANCE
AGREEMENT. 
 4.7.11 Sec. 377 of the German Commercial Code (HGB) is expressly excluded. 

4.8 Risk Management and Business Continuity Plan 

***Confidential Treatment Requested 

  
 Page 24 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 4.8.1 Risk Management. In order to ensure continuity of supply of PRODUCT and in connection with
diligent risk management practices, BI will develop, implement and keep current a risk management program, including a Business Continuity Plan and business continuity plans with its suppliers of critical components. As used herein, a “critical
component” means any component, item, material or service required to manufacture or transport DRUG SUBSTANCE or PRODUCT and for which no suitable replacement is readily available in time to meet obligations regarding shipment date, quantity or
quality of DRUG SUBSTANCE or PRODUCT. [...***...]. 
 4.8.2 “Business Continuity
Plan” shall mean a plan detailing strategies for responses to and recovery from a range of potential disruptive events and clearly defining and documenting a set of measures designed to (i) allow for a quick response to a disruptive
event so that the business process is restored to the minimum required operational level and/or (ii) recover the business process in a defined time frame. Such plan shall cover in particular all key personnel, resources, services and actions
which are required to manage the business continuity management process, and identify available alternative facilities, infrastructure and adequate inventories. Additionally, the Business Continuity Plan shall provide for security and protective
measures necessary to ensure minimal impact of the range of potential disruptive events on HORIZON. The Business Continuity Plan is attached to this AGREEMENT as Exhibit 15 and may be revised from time to time by the Parties’ written
agreement. HORIZON shall have the right to review the then-current Business Continuity Plan at the FACILITY. 
 4.8.3 BI shall have in place an adequate
business continuity plan with its suppliers of critical components, which plan shall include, without limitation, retaining alternative back-up supply to the extent such back-up supply can be made available on commercially reasonable terms and
regularly reviewing all such back-up supply and its ability to supply at short notice. 
 4.8.4 HORIZON shall have the right to inspect and review the
Business Continuity Plan and the business continuity plans with its suppliers of critical components in the course of HORIZON’s scheduled visits at the FACILITY. 

4.9 Continuity of Supply 
 4.9.1 BI acknowledges that it is
critical that HORIZON be ensured continuity of supply of DRUG SUBSTANCE and PRODUCT for use in clinical trials and market supply. BI shall ensure continuity of supply of DRUG SUBSTANCE and PRODUCT for use in clinical trials and market supply.
Nevertheless, due to the potentially growing market demand of PRODUCT, BI’s ability to manufacture and supply DRUG SUBSTANCE and PRODUCT shall be carefully observed by HORIZON. 

4.9.2 BI shall supply the ordered quantities of DRUG SUBSTANCE to HORIZON in accordance with the respective HORIZON order. In the event of a MATERIAL SUPPLY
BREACH, the matter of second source manfacture of DRUG SUBSTANCE and/or PRODUCT 
 ***Confidential Treatment Requested 

  
 Page 25 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 and any potential next steps shall be discussed in good faith by the Parties’ executive officers,
subject to the remainder of this Section 4.9. 
 4.9.3 Should at any time BI have any indication that continuity of supply for PRODUCT can not be
ensured, BI shall immediately inform HORIZON thereof in writing. In event HORIZON or BI reasonably believes there may be an interruption in supply, the matter would be immediately forwarded to executive officers of each Party to discuss second
source manufacture of PRODUCT reasonably and in good faith. 
 4.9.3.1 In the event the STEERING COMMITTEE decides that it is appropriate for HORIZON to
establish a second source manufacturer for PRODUCT (e.g. in case of other PRODUCT formats not sourced from BI as described in Section 4.3.2), HORIZON agrees to provide the first opportunity to qualify as a second source manufacturer for PRODUCT
to a BI AFFILIATE. Accordingly, BI shall promptly nominate a BI AFFILIATE as such a second source manufacturer and, if such BI AFFILIATE is approved by HORIZON, shall use its commerically reasonable efforts to qualify such BI AFFILIATE pursuant to
timelines as mutually agreed by the Parties. If such an AFFILIATE is unable to demonstrate to HORIZON’s reasonable satisfaction that it will be able to supply HORIZON’s requirements then HORIZON shall be free to choose an alternate
supplier for PRODUCT. In this case BI shall assist HORIZON in transferring the MANUFACTURING PROCESS for PRODUCT to a THIRD PARTY supplier by providing reasonable technical assistance and documentation as necessary for a transfer to a party well
skilled in the manufacture of such biotech products at HORIZON’s cost. 
 4.9.4 In addition, the Parties, through the STEERING COMMITTEE, shall work
together in good faith to develop a risk mitigation plan to minimise any risk of interruption in the supply PRODUCT for use in clinical trials and market supply, which plan may include, among other things, production of excess PRODUCT, DRUG
SUBSTANCE or materials relating thereto that can be used as a buffer and/or the off-site storage of certain PRODUCT, DRUG SUBSTANCE or materials relating thereto. 

4.10 Material Supply Breach 
 4.10.1 In the event of a
MATERIAL SUPPLY BREACH, HORIZON shall provide BI written notification of such MATERIAL SUPPLY BREACH. 
 4.10.2 Upon BI’s receipt of such notice the
Parties shall agree in writing upon a timetable and activity plan to cure such MATERIAL SUPPLY BREACH as promptly as possible (the “CURE PLAN”). If the Parties fail to agree upon such a CURE PLAN within [...***...] from the date of notice of such MATERIAL SUPPLY BREACH, or if BI fails to comply with such CURE PLAN, or if despite BI’s compliance with the CURE PLAN, BI cannot cure the
MATERIAL SUPPLY BREACH, then HORIZON shall have the right to purchase from a second source manufacturer, to be agreed upon within the STEERING COMMITTEE in accordance with Section 7.4, such amounts of PRODUCT as necessary to offset BI’s
shortfall in fulfilling HORIZON’s purchase orders for such PRODUCT (or the anticipated shortfall). 
 ***Confidential Treatment
Requested 

  
 Page 26 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 4.10.3 BI shall evaluate its capabilities and, as applicable, promptly nominate a BI AFFILIATE as a second
source manufacturer and, if such BI AFFILIATE is approved by HORIZON, shall use its commerically reasonable efforts to qualify such BI AFFILIATE as promptly as possible. In the event that: 

(i) a BI AFFILIATE can not qualify as a second source manufacturer for PRODUCT or DRUG SUBSTANCE, as applicable, or such a BI AFFILIATE is unable to
demonstrate to HORIZON’s reasonable satisfaction that it will be able to supply HORIZON’s PRODUCT or DRUG SUBSTANCE requirements, and 

(ii) provided that PRODUCT or DRUG SUBSTANCE supply as requested by HORIZON by a different second source manufacturer, a company experienced in
manufacturing of biopharmaceuticals derived from [...***...], and selected by HORIZON could demonstrably take place earlier than a MATERIAL SUPPLY BREACH by BI could be remedied, BI
shall assist HORIZON as requested in transferring the MANUFACTURING PROCESS to such a second source supplier in accordance with Section 14.4. 
 4.10.4
In the event that BI reasonably anticipates that there is a substantial likelihood that a MATERIAL SUPPLY BREACH will occur, BI shall immediately notify HORIZON in writing thereof. Upon receipt of such notice, the Parties shall immediately confer to
discuss the circumstances and magnitude of such potential MATERIAL SUPPLY BREACH, and to determine in good faith whether there are any steps that BI could take to avoid such MATERIAL SUPPLY BREACH. If HORIZON is not reasonably satisfied that BI will
be able to avoid such MATERIAL SUPPLY BREACH, then HORIZON shall forward this issue to the STEERING COMMITTEE to determine whether it is necessary or desirable to establish a second source manufacturer to prevent such a MATERIAL SUPPLY BREACH from
occurring. 
 4.10.5 Nothing in this Section 4.10 shall affect HORIZON’s rights under Section 14 of this AGREEMENT or any right or remedy
otherwise available to HORIZON in connection with such MATERIAL SUPPLY BREACH. 
 4.11 Manufacturing [...***...] Commitment 

BI shall maintain at all times during the term of this Agreement [...***...] manufacturing [...***...] at the FACILITY that has been approved by
the applicable HEALTH AUTHORITIES for the manufacture of PRODUCT. In the event a change in the fill and finish manufacturing [...***...] at the FACILITY due to, e.g., state-of-the art upgrades, would be required after [...***...], the
PARTIES shall agree on a transfer plan and associated work packages for such fill and finish line transfer, FMEA (failure mode effect analysis) and drug product validation which would be covered by HORIZON as CHANGE ORDER. 

4.12 Extension of Territory 

***Confidential Treatment Requested 
  

  
 Page 27 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 If HORIZON desires to extend the TERRITORY, e.g., to include
[...***...], the Parties shall in accordance with Section 15.9 negotiate in good faith an amendment to this AGREEMENT, which shall include agreement on the required measures and
cGMP and associated costs. 
 5. PRICES AND PAYMENT 

5.1 The price of PRODUCT for clinical and market supply are set forth in Exhibit 10. Commencing in [...***...], the price for the PRODUCT
as set forth in Exhibit 10 will be adjusted year by year in accordance with [...***...]. Payments by HORIZON to BI under this AGREEMENT shall be in EUROS.  

5.2 [...***...] will be [...***...] which are [...***...] at the time such [...***...]. [...***...], BI shall only
purchase and maintain at any given time such quantities of COMPONENTS as reasonably necessary to manufacture and supply the PRODUCT to HORIZON in accordance HORIZON’s forecast and this AGREEMENT and shall use reasonable efforts to maintain the
level of inventory of COMPONENTS to a [...***...]. [...***...] shall be entitled [...***...] selected by [...***...], which [...***...] on verification concerning [...***...]. BI shall provide HORIZON with
[...***...] prior notice of any price adjustment.  
 5.3 BI shall submit to HORIZON appropriate invoices for the price of the DELIVERED
MATERIAL and any fees for services agreed upon by the Parties; provided, however, that with respect to the price of the DELIVERED MATERIAL, BI shall submit invoices therefor only [...***...] of DELIVERED MATERIAL by BI according to
Section 4.6. The price for DELIVERED MATERIAL or any services agreed by the Parties shall be paid to BI no later than [...***...] after the date that BI’s invoice is received by HORIZON. Payment of the invoice amounts shall be made
in Germany, [...***...], into an account as stated in the respective invoice, which account may change from time to time.  
 5.4 All
payments owed to BI by HORIZON on the basis of accounts rendered shall be made in such a way that [...***...] shall [...***...] on such [...***...]. In the event of a default in payment for whatever reason, default interest at a
rate of [...***...] p.a. shall be payable on the outstanding amount due. BI  
 ***Confidential Treatment Requested 

  
 Page 28 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 reserves the right to claim any damage exceeding such amount that shall have been caused by
such delay, subject to Section 12.1. 
 5.5 Fees for additional services. As consideration for any additional development
work and/or additional commercial services pursuant to this AGREEMENT to be agreed upon by the Parties and covered in a CHANGE ORDER, HORIZON shall pay to BI the fees as set forth in such CHANGE ORDER and corresponding billing plan set forth in
Exhibit 9.  
 6. QUALITY ASSURANCE AND COMPLIANCE WITH
LAW 
 6.1 Quality Assurance Agreement. Simultaneously with the execution of this Agreement, or prior to such execution, the
Parties shall amend and update the QUALITY ASSURANCE AGREEMENT. Such amended and updated QUALITY ASSURANCE AGREEMENT is hereby incorporated by reference herein and that it shall apply to any DRUG SUBSTANCE and PRODUCT produced under this AGREEMENT.
The QUALITY ASSURANCE AGREEMENT shall in no way determine liability or financial responsibility of the Parties for the responsibilities set forth therein. In the event of a conflict between any of the provisions of this Agreement and the QUALITY
ASSURANCE AGREEMENT in matters of business, financial or legal nature, the terms of this Agreement shall control and for matters of quality processes (including with respect to PRODUCT disposition), the terms of the Quality Agreement shall
prevail.The QUALITY ASSURANCE AGREEMENT may be amended from time to time by the Parties only in accordance with Section 15.9.  
 6.2
Manufacturing Facilities 
 BI represents and warrants that it shall obtain all relevant APPROVALS required by the relevant HEALTH AUTHORITIES for the
FACILITY and that its and its AFFILIATES’ respective manufacturing facilities conform, and will during the term of this AGREEMENT conform, to cGMP. 

6.3 Compliance with Law 
 6.3.1 BI shall comply, and shall
ensure that its AFFILIATES and PERMITTED SUBCONTRACTORS comply, with all applicable rules, laws and regulations in [...***...], as applicable to a biopharmaceutical manufacturer in
[...***...] (including without limitation cGMP) in performing its obligations under this AGREEMENT. HORIZON shall comply with all applicable rules, laws and regulations in performing its obligations under this AGREEMENT. 

6.3.2 All costs in connection with maintaining BI’s compliance with all applicable regulatory requirements applicable to a biopharmaceutical manufacturer
in [...***...] and cGMP in performing under this AGREEMENT, including but not limited to the maintenance and upgrading of technical facilities and infrastructure and the training of personnel, shall be borne by [...***...].
[...***...] 
 ***Confidential Treatment Requested 

  
 Page 29 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...]. All costs in connection with
any requirements by (i) HORIZON or a (ii) HEALTH AUTHORITY which relate specifically and solely to the PRODUCT shall be [...***...], provided that to the extent that such requirements arise due to the manufacture, use, sale or other
disposition of IMUKIN PRODUCT [...***...] prior to the Closing Date (as defined in the ASSET PURCHASE AGREEMENT), [...***...]. 
 6.3.3 If a
HEALTH AUTHORITY requests or requires that a change be made to the DRUG SUBSTANCE SPECIFICATIONS, PRODUCT SPECIFICATIONS or the MANUFACTURING PROCESS, then BI shall make such changes in accordance with the QUALITY ASSURANCE AGREEMENT and SOPs (i.e.,
change control procedures) agreed in writing by HORIZON and BI. Those changes are subject to written approval of each Party, which approval shall not be unreasonably withheld, delayed or conditioned. In case that a request from a HEALTH AUTHORITY
may be challenged by either Party, HORIZON and/or BI shall use commercially reasonable efforts to challenge the requests of the HEALTH AUTHORITY and shall assist each other in its communication with the pertinent HEALTH AUTHORITY requesting such a
change. The costs for such a change shall be allocated between the Parties according to Section 6.3.2. 
 6.3.4 If HORIZON desires (for any reason other
than a request or requirement by a HEALTH AUTHORITY), to change the DRUG SUBSTANCE SPECIFICATIONS, PRODUCT SPECIFICATIONS or the MANUFACTURING PROCESS, then BI shall use reasonable commercial efforts to accommodate such request, subject to the
remainder of this Section 6.3.4 below. 
 6.3.4.1 HORIZON shall promptly advise BI in writing of any such change(s), and provide information necessary
for BI to evaluate the effect of such change(s). BI shall promptly advise HORIZON as to scheduling changes, if any, which may result from such change(s). The notification and approval procedure shall be in accordance with SOPs (i.e. change control
procedures) agreed by the Parties from time to time, as described in the QUALITY ASSURANCE AGREEMENT. The Parties shall hold a meeting in a timely manner to discuss such changes as appropriate. 

6.3.4.2 Prior to implementation of any change(s), BI shall provide HORIZON with a quote of the price of the services (which price shall be reasonable in nature
and consistent with industry standards) and COMPONENTS that will be provided and purchased by BI in order to implement any such change(s) to the DRUG SUBSTANCE SPECIFICATIONS, PRODUCT SPECIFICATIONS or the MANUFACTURING PROCESS, including, but not
limited to, the price of BI’s validation and analytical services. If such changes will be implemented, then HORIZON shall pay the price of the services and COMPONENTS described in this Section. 

6.3.4.3 BI shall make changes as described in this Section 6.3.4 in accordance with timelines agreed to by the Parties, except that BI shall have no
obligation to make any such change where doing so, (i) in BI’s reasonable judgment after due consultation with legal counsel having experience in such matters, which shall be communicated in writing to HORIZON, would violate 

***Confidential Treatment Requested 

  
 Page 30 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 any applicable law or regulations, or (ii) has a material adverse effect upon any regulatory filings for
other products of BI or (iii) would be incompatible with BI’s established operations for biopharmaceuticals. For all changes requested by HORIZON, BI shall cooperate with HORIZON in good faith to implement all agreed upon changes to DRUG
SUBSTANCE SPECIFICATIONS, PRODUCT SPECIFICATIONS or the MANUFACTURING PROCESS in accordance with the timelines agreed to by the Parties according to this Section 6.3.4.3. 

6.3.5 HORIZON acknowledges and agrees that the Parties must agree in advance as of which point in time and to which manufacture of BATCHES of DRUG SUBSTANCE or
PRODUCT changes to the DRUG SUBSTANCE SPECIFICATIONS, PRODUCT SPECIFICATIONS or the MANUFACTURING PROCESS apply. However, HORIZON acknowledges and agrees that changes to the DRUG SUBSTANCE SPECIFICATIONS, PRODUCT SPECIFICATIONS or the MANUFACTURING
PROCESS during an ongoing campaign are not possible. 
 6.3.6 If any changes to the DRUG SUBSTANCE SPECIFICATIONS, PRODUCT SPECIFICATIONS or the
MANUFACTURING PROCESS render obsolete or unusable any COMPONENTS and if and to the extent those COMPONENTS may not be returned to the appropriate vendor for a credit, BI shall either destroy or deliver to HORIZON, at HORIZON’s sole option,
those obsolete or unusable COMPONENTS. HORIZON shall reimburse BI for the costs of such COMPONENTS destroyed or provided to HORIZON to the extent the amount of COMPONENTS that would have been reasonably required for BI to maintain in inventory in
order to meet its obligations under this AGREEMENT (consistent with its obligations under Section 5.2 hereof with respect to the COMPONENTS). 
 6.3.7
HORIZON may request additional regulatory services support from BI (e.g., those set forth in Sections 3.1.2.3 and 3.2) with respect to the DRUG SUBSTANCE or PRODUCT, in support of either obtaining or maintaining regulatory approval in any country of
the TERRITORY. In such event, BI shall provide a quote of the price of such services (which pricing shall be reasonable in nature and consistent with industry standards), and shall provide such additional regulatory services upon mutual agreement on
the scope and price of such services. For purposes of clarity and notwithstanding anything to the contrary contained in this Agreement, for purposes of maintaining regulatory approvals existing as of the EFFECTIVE DATE of this Agreement in any
country of the TERRITORY, BI will draw up the annual report required by the HEALTH AUTHORITIES pursuant to Section 3.1.2.5, [...***...], without additional cost or expense to
HORIZON. All costs for any further stability studies requested by HORIZON shall be borne by HORIZON, unless such further stability studies are necessary due to BI’s breach of this AGREEMENT, in which event BI shall bear the costs thereof.
HORIZON will inform BI in due time which regulatory support is requested from BI. Further, all costs for any translation services that relate solely to such regulatory services support from BIshall be borne directly by HORIZON. 

 

	6.3.8	HORIZON shall bear the costs for HEALTH AUTHORITY regulatory inspections 

 ***Confidential
Treatment Requested 

  
 Page 31 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 that are solely related to PRODUCT as set forth in Section 6.3.2 and Exhibit 14. With respect to
HEALTH AUTHORITY regulatory inspections that are substantially related to PRODUCT as well as other products, Horizon shall bear such costs proportionally to the amount of time such inspection is specifically directed to the PRODUCT relative to the
entirety of the inspection, and solely to the extent that such costs are not incurred by BI in the ordinary course of its business. For clarity, any costs incurred in connection with inspections that relate to the manufacture, use, sale or other
disposition of IMUKIN PRODUCT by or on behalf of BI prior to the Closing Date (as defined in the ASSET PURCHASE AGREEMENT) shall be borne by BI. 
 6.4
Environmental 
 BI shall ensure proper disposal of any and all hazardous waste materials involved with the manufacture of DRUG SUBSTANCE and PRODUCT
that are generated or resulting from the activities performed hereunder, if any, in full compliance with all applicable laws and regulations at BI’s sole liability and expense. 

6.5 Person-in-Plant 
 During the term of
this AGREEMENT HORIZON may reasonably request that up to [*...***...] experienced technical or quality personnel of HORIZON, which may be employees or contractors, (each, a
“PIP”) be present at the FACILITY during manufacture under this AGREEMENT, to the extent set forth below, for the purpose of observing manufacturing of PRODUCT or DRUG SUBSTANCE, participating in reviews, acting as liaison / single
point of contact between HORIZON and BI with respect to MANUFACTURING PROCESS related issues and performing such other actions set forth in the QAA. Such PIP shall be entitled to make decisions on quality and/or technical matters related to the
PRODUCT and DRUG SUBSTANCE. HORIZON shall provide BI with [...***...] notice of such visit by such PIP specifying the function of the PIP. The role, rights and obligations of the PIP when present at the FACILITY shall be as set forth below in
this section, together with any additional responsibilities, authorities and obligations as may be set forth in the QAA. 
 The PIP’s
presence at the FACILITY shall be limited to the active manufacturing operational hours of the PRODUCT and DRUG SUBSTANCE and the PIP’s access to the FACILITY shall be limited to MANUFACTURING PROCESS steps in accordance with a mutually agreed
schedule. 
 BI shall ensure that the PIP at the FACILITY is kept reasonably informed of the relevant issues which may affect the PRODUCT
and/or DRUG SUBSTANCE quality and will use the PIP to coordinate the performance of activities with respect thereto that are the responsibility of HORIZON. 

The PIP at the FACILITY shall at all times: 
  

	 	•	 	be accompanied by BI’s personnel for safety and confidentiality reasons; and 

***Confidential Treatment Requested 

  
 Page 32 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

	 	•	 	observe BI’s house rules, regulations, confidentiality rules and requirements, standard procedures, safety requirements and security procedures, to the extent previously disclosed in writing by BI to HORIZON; and

  

	 	•	 	operate in a manner as not to adversely interfere with operations at the FACILITY or at the premises, and not give any instruction to BI or personnel; and 

 

	 	•	 	respect any instructions provided by BI regarding presence in the FACILITY and overall use of BI’s premises and EQUIPMENT at the FACILITY. 

With respect to any PIP present at the FACILITY during the term of this AGREEMENT, BI shall provide, at no cost to HORIZON, (i) space in
an on-site office along with reasonable access to conference rooms (as necessary for meetings and telephone conferences of a proprietary nature), routine office supplies, parking, and cafeteria facilities; (ii) reasonable access to and use of
high-speed internet (but not BI’s intranet) and photocopying services and (iii) such other reasonable and customary business accommodations as are necessary for such PIP to perform its activities as described above. 

HORIZON shall comply with all responsibilities under applicable laws concerning the employment or engagement of the PIP. In addition, HORIZON
shall ensure that the PIP will be fully insured while working at the FACILITY. HORIZON acknowledges that according to local immigration and/or employment laws, BI may need to obtain a deployment authorization for the PIP from the local authorities
before any scheduled visit of the PIP to the FACILITY. HORIZON and the respective PIP shall timely provide BI with the necessary information requested by BI, and BI shall timely process such information, to request a deployment authorization for the
PIP from the local authorities. HORIZON further acknowledges that notwithstanding BI ́s diligent processing of such a request, the six-week notification period set forth above may not be sufficient to secure a deployment authorization, if
necessary, before the scheduled visit to the FACILITY. 
 HORIZON shall bear its own costs with respect to the PIP’s presence at the
FACILITY and BI shall not charge fees for any PIP’s presence. 
 7.
CO-OPERATION AND CO-ORDINATION BETWEEN THE PARTIES 

7.1 PROJECT LEADER 
 In order to implement the additional
services for [...***...], and in any case the PARTIES agree to introduce other changes to the MANUFACTURING PROCESS and/or the DRUG SUBSTANCE or the PRODUCT, such changes shall be
agreed upon and implemented in the format of a project. Upon commencement of a project, BI and HORIZON will each appoint a project leader (“PROJECT LEADER”), who will coordinate and supervise the project including communication of
all instructions and information concerning the project to the other Party. The PROJECT LEADER will serve as contact person for the other Party. Each PROJECT LEADER 

***Confidential Treatment Requested 

  
 Page 33 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 will be available on an agreed (monthly) basis for consultation at prearranged times during the course of the
Project. The PROJECT LEADERs shall be copied on all correspondence by other JOINT PROJECT TEAM members and all correspondence between the PARTIES. In the absence of the PROJECT LEADER, a substitute shall be appointed. Additional modes or methods of
communication and decision making may be implemented with the mutual written consent of each PARTY. Each PARTY will use reasonable efforts to provide the other PARTY with [...***...]
prior written notice of any change in such Party’s PROJECT LEADER. 
 7.2 JOINT PROJECT TEAM 

7.2.1 The PARTIES shall establish a JOINT PROJECT TEAM consisting of the necessary disciplines and their respective PROJECT LEADER to (i) ensure the
progress of the project, (ii) coordinate the performance of the project, and (iii) facilitate communication among the PARTIES. Each JOINT PROJECT TEAM member shall have knowledge and ongoing familiarity with the project and will possess
the authority to make decisions on matters likely to be raised in the JOINT PROJECT TEAM. Each PARTY shall have the right to substitute its members of the JOINT PROJECT TEAM as needed from time to time by giving written notice to the other PARTY due
time in advance. 
 7.2.2 The JOINT PROJECT TEAM shall meet in person or by means of a video conference or teleconference on a periodic basis (i) as
agreed by the PROJECT LEADERS after written request for such meeting by either PARTY, or (ii) as specified in the project plan, as amended from time to time. 

7.2.3 The JOINT PROJECT TEAM shall oversee a project. Prior to each meeting of the JOINT PROJECT TEAM the PARTIES will distribute to each other written copies
of all reasonably necessary materials, data and information arising out of the conduct of their activities hereunder. 
 7.2.4 Each PARTY shall bear its own
costs associated with such meetings and communications. It is the right of each PARTY to call for a JOINT PROJECT TEAM meeting according to the covenants of this Section 7.2 in writing (e-mail sufficient) at any time. In such case the meeting
will be held at the other PARTY’s offices (or by means of videoconference or teleconference upon suggestion of the requesting PARTY) at a time mutually agreed to by both PROJECT LEADERS. 

7.2.5 In the event that the JOINT PROJECT TEAM is unable to reach agreement on any issue and is unable to make decisions arising out of operational and
scientific issues within [...***...], each PARTY may call in an expert of its own choice to render advice to the JOINT PROJECT TEAM. Based on the advice of such expert(s) and the team members’
know-how, the JOINT PROJECT TEAM will try to resolve such issue. In the event that the PROJECT TEAM fails to reach agreement on an issue within [...***...] of first undertaking resolution of such issue,
such issue shall then be referred to the STEERING COMMITTEE for immediate resolution. 
 ***Confidential Treatment Requested 

  
 Page 34 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 7.2.6 The JOINT PROJECT TEAM shall have no authority to amend this Agreement, including any Appendix or
CHANGE ORDER. The JOINT PROJECT TEAM shall recommend to the STEERING COMMITTEE for approval changes to any planned activities that are expected to result in increased costs to HORIZON, but shall have no authority itself to approve such activities.

 7.3 PRODUCT Team 
 7.3.1 The day-to-day
responsibilities of the Parties with respect to this AGREEMENT shall be overseen by the PRODUCT TEAM, which shall be responsible for deciding operational and scientific issues arising out of this AGREEMENT and unanimously agreeing in good faith with
respect to the monitoring of the compliance with this AGREEMENT. 
 7.3.2 The PRODUCT TEAM shall consist of a team consisting of equal numbers of people, if
feasible, each appointed by HORIZON and BI and notified to the other, which appointees may be changed from time to time by the appointing Party on written notice to the other Party. Each member of the PRODUCT TEAM shall be a person of appropriate
skill and experience. Either Party may change its own designated PRODUCT TEAM members provided, however, that the total number of members of the PRODUCT TEAM may not be changed, if feasible, nor the number of members representing HORIZON decreased,
without the Parties’ prior written agreement. HORIZON’s and BI’s respective functions of the PRODUCT TEAM as of the Effective Date are listed in Exhibit 8.  

7.3.3 During the term of this AGREEMENT, the PRODUCT TEAM shall meet regularly to communicate updates and provide a forum for
decision-making and rapid resolution of issues arising under this AGREEMENT. Meetings of the PRODUCT TEAM may be conducted by telephone conference, videoconference or face-to-face meetings as agreed by the PRODUCT TEAM. 
 7.3.4 Decisions of the PRODUCT TEAM shall be reflected in
the approved minutes. Meeting minutes shall be prepared in alternate turns by the Parties by the respective PRODUCT MANAGERS of the relevant Party to record all issues discussed and decisions. The Party responsible for meeting minutes shall provide
the other Party herewith no later than [...***...] after the relevant meeting has taken place. Minutes that have not been objected to in writing by a Party within said
[...***...] of receipt thereof shall be deemed approved by such Party and followed by issuance of the minutes duly executed by the Parties’ PRODUCT MANAGER. 

7.3.5 In the event that the PRODUCT TEAM is unable to reach agreement on any issue and is unable to make decisions arising out of operational and scientific
issues within [...***...], each PARTY may call in an expert of its own choice to render advice to the PRODUCT TEAM. Based on the advice of such expert(s) and the team members’ know-how, the PRODUCT
TEAM will try to resolve such issue. In the event that the PRODUCT TEAM fails to reach agreement on an issue within [...***...] of first undertaking 

***Confidential Treatment Requested 

  
 Page 35 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 resolution of such issue, such issue shall then be referred to the STEERING COMMITTEE for immediate
resolution. 
 7.4 Steering Committee 
 7.4.1 The Parties
shall create a STEERING COMMITTEE consisting of authorized representatives who shall be appointed by HORIZON and by BI in equal numbers, if feasible, and notified to the other Party. The STEERING COMMITTEE shall be responsible for unanimously
agreeing in good faith all issues on which the JOINT PROJECT TEAM and/or the PRODUCT TEAM has been unable to reach agreement or that are otherwise delegated under this AGREEMENT to the STEERING COMMITTEE for resolution, and, where possible, make
decisions arising out of such issues as well as carry out the specific functions, including but not limited to decisions with an impact on costs and timelines of any activities to be carried out under this AGREEMENT. Each Party may change its own
designated STEERING COMMITTEE members by providing written notice thereof to the other Party; provided, however that the total number of members of the STEERING COMMITTEE may not be changed, if feasible, nor the number of members representing
HORIZON decreased, without the Parties’ prior written agreement. The functions of the STEERING COMMITTEE are listed in Exhibit 8.  
 7.4.2 The
STEERING COMMITTEE shall attempt in good faith to expeditiously and fairly resolve all issues before it. In the event that the STEERING COMMITTEE is unable to resolve any issue before it within
[...***...] from the date that such issue is referred to it, such issue shall be referred to the Chief Executive Officer of HORIZON and BI’s Managing Director for prompt, good
faith resolution. If such individuals do not reach agreement on such issue within [...***...] of such referral, then each Party shall be free to pursue all available legal and/or equitable remedies. 

7.4.3 Notwithstanding Section 7.4.2, and solely with respect to the determination (a) pursuant to Section 4.9 of whether it is appropriate for
HORIZON to engage a second source manufacturer for the manufacture of other PRODUCT formats not sourced from BI as described in Section 4.3.2 or (b) pursuant to Section 4.10.4 of whether it is necessary or desirable to establish a
second source manufacturer to prevent such a MATERIAL SUPPLY BREACH from occurring, HORIZON shall in each case have the right to make the final decision on behalf of the STEERING COMMITTEE, without prejudice to Section 14.4. 

7.4.4 Decisions of the STEERING COMMITTEE shall be reflected in approved minutes. Meeting minutes shall be prepared by the Parties in alternate turns to record
all issues discussed and decisions and the responsible Party shall provide the other Party with a draft for review no later than [...***...] after the relevant meeting has taken place. Minutes that have not been objected to in writing by a
Party within [...***...] of receipt thereof shall be deemed approved by such Party and followed by issuance of the minutes duly executed by the relevant members of the STEERING COMMITTEE. 

7.5 Limitation of Powers 

***Confidential Treatment Requested 

  
 Page 36 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 The powers of the PROJECT TEAM, PRODUCT TEAM and/or the STEERING COMMITTEE are limited to those expressly set
forth in this AGREEMENT. Without limiting the generality of the foregoing, neither the PROJECT TEAM, PRODUCT TEAM nor the STEERING COMMITTEE shall have the right to amend this AGREEMENT or waive compliance with any provision hereof. The actions of
the PROJECT TEAM, the PRODUCT TEAM and/or the STEERING COMMITTEE shall not substitute for either Party’s ability to exercise any right, nor excuse the performance of any obligation, set forth herein. 

8. INTELLECTUAL PROPERTY AND LICENSES 

8.1 The ownership of HORIZON BACKGROUND IP and PRODUCT is and shall remain with HORIZON and shall not vest in BI. 

8.2 The ownership of BI’S BACKGROUND IP is and shall remain with BI and shall not vest in HORIZON. 

8.3 HORIZON shall have the exclusive ownership of all HORIZON IMPROVEMENTS.
[...***...]. BI agrees to assign and hereby assigns to HORIZON all right title and interest it may have in any HORIZON IMPROVEMENTS. BI shall ensure that all entities and individuals
that perform any work are subject to an obligation to assign (directly or through their employer) all rights in an HORIZON IMPROVEMENTS to BI, so that they may be further assigned to HORIZON as set forth above. BI shall provide reasonable assistance
to HORIZON for any action which may be necessary to assign or otherwise transfer any rights to HORIZON IMPROVEMENTS contemplated by this Section 8.3. BI shall notify HORIZON in writing within [...***...] of becoming aware of any HORIZON
IMPROVEMENTS. 
 8.4 BI shall have the exclusive ownership of all BI IMPROVEMENTS. [...***...]. HORIZON agrees to assign and hereby assigns to
BI (and/or any designated AFFILIATE) all right, title and interest it may have in any BI IMPROVEMENTS. HORIZON shall ensure that all entities and individuals that perform any work are subject to an obligation to assign (directly or through their
employer) all rights in BI IMPROVEMENTS to HORIZON, so that they may be further assigned to BI (and/or any designated AFFILIATE) as set forth above. HORIZON shall provide reasonable assistance to BI (and/or any designated AFFILIATE) for any action
which may be necessary to assign or otherwise transfer such rights to BI IMPROVEMENTS contemplated by this Section 8.4. 
 8.5 BI hereby grants
to HORIZON a non-exclusive, perpetual (subject to Horizon’s payment of all undisputed amounts under this AGREEMENT), sublicenseable (through multiple tiers), royalty free license under the BI IMPROVEMENTS and BI BACKGROUND IP (i) to the
extent necessary to develop, use, import, offer for sale and sell products containing INTERFERON GAMMA 1b in the name and on the account of HORIZON (or its successor in interest) throughout the world, and (ii) in the event HORIZON is entitled
to request a TECHNOLOGY TRANSFER in accordance with Section 14.4.1, to make and have made products containing INTERFERON GAMMA 1b in the name and on account of HORIZON (or 

***Confidential Treatment Requested 

  
 Page 37 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 its successor in interest) throughout the world, whereby in each case HORIZON shall assume the costs to be
paid by BI for awards to inventors of BI IMPROVEMENTS, as such awards are set forth in written agreements between BI and such inventor or in an applicable industry labor contract or mandatory by applicable laws, but solely to the extent that BI has
given HORIZON written notice of such costs and inventors. 
 8.6 HORIZON hereby grants to BI a non-exclusive,
nonsublicensable (except to BI’s AFFILIATES and PERMITTED SUBCONTRACTORS solely to perform the services under and in accordance with this Agreement, without the right to further sublicense) license to use HORIZON BACKGROUND IP and HORIZON
IMPROVEMENTS solely for the purpose of manufacturing PRODUCT and DRUG SUBSTANCE for HORIZON, as provided in this AGREEMENT. The license granted under this Section 8.6 shall automatically terminate upon the expiration or effective termination of
this AGREEMENT. 
 9. COMPLAINTS; ADVERSE EVENTS; RECALLS 

9.1 Each Party shall inform the other Party of any complaints, adverse reaction reports, safety issues or toxicity issues relating to any PRODUCT in
accordance with the SDEA (as defined in Section 3.1.2.2) and/or the QUALITY ASSURANCE AGREEMENT. 
 9.2 Recalls 

9.2.1 HORIZON shall notify BI within [...***...] if any DELIVERED MATERIAL (including,
without limitation, clinical trial material) manufactured by BI hereunder is the subject of a recall, withdrawal or correction, and HORIZON and/or its designee shall have the sole responsibility for the handling and disposition of such recall,
market withdrawal or correction. In the event that a recall is required directly due to BI’s breach of any of its warranties set forth in Section 10.2 hereof, BI shall reimburse HORIZON for the purchase price of such DELIVERED MATERIAL and
all other reasonable costs and expenses associated with such DELIVERED MATERIAL recall, market withdrawal or correction, but only to the extent that the foregoing costs and expenses are attributable to BI’s breach of its warranties hereunder.
In all other events of a recall, all costs and expenses incurred in connection with such PRODUCT recall shall be borne by HORIZON, and BI shall be entitled to charge HORIZON for reasonable costs and expenses for [BI’s] support to HORIZON in
handling a recall. Notwithstanding the foregoing, if each of BI and HORIZON contribute to the cause of a recall, the costs and expenses shall be shared in proportion to each Party ́s responsibility, provided however that the limitation of
liability according to Section 12 shall apply. HORIZON and/or its designee shall serve as the sole point of contact with the FDA or other applicable HEALTH AUTHORITY concerning any recall, market withdrawal or correction with respect to the
DELIVERED MATERIAL. 
 9.3 Insurance 
 During the term of
this AGREEMENT and following the term of this Agreement for the remainder of the shelf life of all DRUG SUBSTANCE and PRODUCT supplied to HORIZON hereunder, the Parties shall maintain product liability insurance in such amounts and with such 

***Confidential Treatment Requested 

  
 Page 38 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 scope of coverage as are adequate to cover the Parties’ obligations under this AGREEMENT and as
appropriate for companies of like size, taking into account the scope of activities contemplated herein. Notwithstanding the foregoing the Parties shall maintain minimum limits of product liability of
[...***...] US$ per occurrence and in the aggregate annually. The Parties shall provide to each other within [...***...] of execution of this AGREEMENT and thereafter, once a
year upon the other Party’s request, a certificate of insurance evidencing the respective Party’s product liability insurance. In addition to the foregoing coverage, the Parties shall maintain Commercial General Liability Insurance for
limits of not less than [...***...] US$ per occurrence and in the aggregate annually for bodily injury and property damage. Notwithstanding the foregoing, BI shall have the right to self-insure at any time that it can demonstrate it has the
financial resources and capabilities to adequately self-insure against the potential liabilities at levels equivalent to or greater than those set forth above, provided that BI gives HORIZON written notice of such self-insurance. If BI self-insures
as set forth above, then it shall provide HORIZON with current information reasonably requested by HORIZON as is necessary to verify BI’s ability to so self-insure. 

10. REPRESENTATIONS AND WARRANTIES 

10.1 Each Party hereby represents and warrants to the other Party that: (a) the person executing this AGREEMENT is authorized to execute this
AGREEMENT; (b) this AGREEMENT is legal and valid and the obligations binding upon such Party are enforceable by their terms; and (c) the execution, delivery and performance of this AGREEMENT does not conflict with any agreement, instrument
or understanding, oral or written, to which such Party may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 

10.2 BI Warranties 
  

	10.2.1	BI represents and warrants (gewährleistet): 

 10.2.1.1 All DRUG SUBSTANCE manufactured hereunder
shall on the MANUFACTURER’S RELEASE date conform to DRUG SUBSTANCE SPECIFICATIONS; 
 10.2.1.2 All PRODUCT manufactured and supplied hereunder shall at
the date of shipment conform to the PRODUCT SPECIFICATIONS; 
 10.2.1.3 All DRUG SUBSTANCE and PRODUCT manufactured and supplied hereunder shall be in
accordance with the applicable MANUFACTURING PROCESS; 
 10.2.1.4 Subject to Section 10.4, all DRUG SUBSTANCE and PRODUCT manufactured hereunder shall
be manufactured, handled, stored, labelled, packaged and transported (within the FACILITY and between the FACILITIES) in accordance with cGMP requirements, the QUALITY ASSURANCE AGREEMENT and all applicable laws, regulations and ordinances of the
jurisdiction in which such manufacture occurs; 
 ***Confidential Treatment Requested 

  
 Page 39 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 10.2.1.5 No DRUG SUBSTANCE or PRODUCT manufactured and supplied to HORIZON hereunder shall be
(i) adulterated or misbranded by BI within the meaning of the FD&C Act, or (ii) an article that may not be introduced into interstate commerce under the provisions of Sections 404 or 505 of the FD&C Act; 

10.2.1.6 BI shall not use in any capacity the services of any persons debarred under 21 U.S.C. sections 335 (a) and 335 (b) in connection with the
manufacture of DRUG SUBSTANCE or PRODUCT under this AGREEMENT; and 
  

	10.2.1.7	BI shall comply with those terms of the [...***...], that are applicable to BI as a sublicensee thereunder. 

10.3 Except as expressly provided for herein, BI makes no further warranties of the merchantability or fitness of the DRUG SUBSTANCE or PRODUCT or any
warranties of any other nature, express or implied.  
 10.4 Notwithstanding the foregoing, BI’s representations and warranties under
Section 10.2.1.4 with respect to compliance with cGMP requirements shall not apply to DRUG SUBSTANCE or PRODUCT manufactured as contemplated in Exhibit 17 and/or in the event of a project performed under Sections 7.1 and 7.2, until BI
manufactured DRUG SUBSTANCE and PRODUCT [...***...], or in the event that an applicable purchase order expressly exempts DRUG SUBSTANCE and/or PRODUCT from compliance with cGMP. 

10.5 For clarification purposes, all BI liability or indemnification obligations that might result from the representations and warranties under this
Section 10 are always subject to the limitations set forth in Section 12 of this AGREEMENT. 
 10.6 In the event of a
breach of a BI Warranty set forth in Section 10.2.1, HORIZON shall be entitled to the remedies set forth in Section 437 German Civil Code (Bürgerliches Gesetzbuch – BGB) in each case irrespective of BI acting culpable
(verschuldensunabhängig).  
 10.7 HORIZON Warranties 
  

	10.7.1	HORIZON represents and warrants (gewährleistet): 

 10.7.1.1 Any excess non-GMP and/or expired DRUG
SUBSTANCE supplied in accordance with Section 4.3.5 will in no event be used in humans. 
  

	10.7.1.2	[...***...]. 

 10.7.2 Except as expressly provided for herein, HORIZON makes no further warranties of any
other nature, express or implied. 
 ***Confidential Treatment Requested 

  
 Page 40 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 10.7.3 In the event of a breach of a HORIZON Warranty set forth in Section 10.7.1, BI shall be entitled
to the remedies set forth in Section 437 German Civil Code (Bürgerliches Gesetzbuch – BGB) in each case irrespective of HORIZON acting culpable (verschuldensunabhängig). 

10.7.4 For clarification purposes, all HORIZON liability or indemnification obligations that might result from the representations and warranties under this
Section 10 are always subject to the limitations set forth in Section 12.1 of this AGREEMENT. 
 11.
LIABILITY/INDEMNIFICATION 
 11.1 Unless this AGREEMENT stipulates otherwise, in the event that a
Party violates its obligations under this AGREEMENT, the violating Party shall be liable in accordance with statutory German law, in particular, Sections 280, 281 German Civil Code (Bürgerliches Gesetzbuch – BGB), subject always to
Section 12. 
 11.2 Subject to Section 11.4 and 12, BI shall indemnify, defend and hold harmless (freistellen)
HORIZON and its AFFILIATES and their respective officers, directors, employees and agents from and against all Third Party costs, claims, (including death and bodily injury) suits, expenses (including reasonable attorneys’ fees), liabilities
and damages (collectively, “LIABILITIES”) arising out of or resulting from (a) any willful or negligent act or omission by BI, its AFFILIATES and/or subcontractors relating to the subject matter of this AGREEMENT, (b) any
failure to deliver DELIVERED MATERIAL in accordance with BI’s warranties, or (c) any breach of this AGREEMENT by BI for which BI is responsible in accordance with Section 276 BGB (except in each case to the extent such LIABILITIES
arose or resulted from any negligent act or omission by HORIZON or breach of this AGREEMENT by Horizon for which HORIZON is responsible in accordance with Section 276 BGB). For clarity, any indemnification of HORIZON by BI according to this
Section 11.2 shall not extend to any LIABILITIES if and to the extent HORIZON is required to indemnify BI according to Section 11.3 below, and shall not exceed BI’s aggregate liability as set forth in Section 12.2 (subject to the
exceptions set forth therein).  
 11.3 Subject to Section 11.4 and 12, HORIZON shall indemnify, defend and hold harmless
(freistellen) BI and its AFFILIATEs and their respective officers, directors, employees and agents from and against all LIABILITIES arising out of or resulting from (a) any willful or negligent act or omission by HORIZON relating to the
subject matter of this AGREEMENT, (b) the use by or administration to any person of DELIVERED MATERIAL manufactured by BI in performance of its obligations under this AGREEMENT or (c) any breach of this AGREEMENT by HORIZON for which
HORIZON is responsible in accordance with Section 276 BGB (except in each case to the extent such LIABILITIES arose or resulted from any negligent act or omission by BI, its AFFILIATES or subcontractors, or any failure to deliver DELIVERED
MATERIAL in accordance with BI’s warranties, or any breach of any other provision of this AGREEMENT for which BI is responsible in accordance with Section 276 BGB). For clarity, any indemnification of BI by HORIZON according to this
Section 11.3 shall not extend to any LIABILITIES if and to the extent arising from any action or omission described in Section 11.2(a), (b) or (c) above.  

  
 Page 41 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 11.4 A Party and its AFFILIATES and their respective directors, officers, employees and
agents which intends to claim indemnification under this Section 11 (each, an “INDEMNITEE”) shall promptly notify the other Party (the “INDEMNITOR”) in writing of any action, claim
or other matter in respect of which the INDEMNITEE intend to claim such indemnification; provided, however, that the failure to provide such notice within a reasonable period of time shall not relieve the INDEMNITOR of any of its obligations
hereunder except to the extent that the INDEMNITOR is prejudiced by such failure. The INDEMNITEE shall permit the INDEMNITOR at its discretion to settle any such action, claim or other matter, and the INDEMNITEE agrees to the complete control of
such defense or settlement by the INDEMNITOR. Notwithstanding the foregoing, the INDEMNITOR shall not enter into any settlement that would adversely affect the INDEMNITEE’s rights hereunder, or impose any obligations on the INDEMNITEE in
addition to those set forth herein in order for it to exercise such rights, without INDEMNITEE’s prior written consent, which shall not be unreasonably withheld or delayed. No such action, claim or other matter shall be settled without the
prior written consent of the INDEMNITOR, which shall not be unreasonably withheld or delayed. The INDEMNITOR shall not be responsible for any attorneys’ fees or other costs incurred other than as provided herein. The INDEMNITEE shall cooperate
fully with the INDEMNITOR and its legal representatives in the investigation and defense of any action, claim or other matter covered by the indemnification obligations of this Section 11. The INDEMNITEE shall have the right, but not the
obligation, to be represented in such defense by counsel of its own selection and at its own expense. 
 12. LIMITATIONS
ON LIABILITY 
 12.1 In no event shall either Party be liable to the other Party for any consequential, incidental,
punitive, special or indirect damages, including, but not limited to, loss of profits, loss of revenue, loss of opportunity or loss of good will, arising in connection with this AGREEMENT except in the case of willful misconduct or willful omission
by such Party. For clarity, this Section 12.1 will not apply with respect to claims for which a Party is required to provide indemnification pursuant to Article 11. 

12.2 Except as set forth in Section 12.1, BI’s maximum aggregate liability (including its indemnification obligation) under this Agreement
shall not exceed [...***...] or the amount of [...***...] Euros, except in the event of BI’s willful misconduct or omission. 

13. CONFIDENTIALITY 
 13.1 Each
Party shall treat confidentially all CONFIDENTIAL INFORMATION of the other Party, and shall not use or disclose such CONFIDENTIAL INFORMATION other than it is expressly permitted under this AGREEMENT. Each Party will take steps to protect the other
Party’s CONFIDENTIAL INFORMATION that are at least as stringent as the steps such Party uses to protect its own CONFIDENTIAL INFORMATION, but in no event shall be less than reasonable. Each Party may disclose the other Party’s CONFIDENTIAL
INFORMATION to employees (including those of its AFFILIATEs), (sub)contractors, advisors, agents and potential 
 ***Confidential Treatment
Requested 

  
 Page 42 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 or actual merger, acquisition or other business partners who reasonably need to know that CONFIDENTIAL
INFORMATION provided that (i) they are bound by written obligations of confidentiality and non-use consistent with those set forth in this AGREEMENT or (ii) that they enter into a legally binding agreeement with the disclosing PARTY
pursuant to which they agree to observe confidentiality privisions which are substantially similar to those set out in this Section 13 or are bound by confidentiality obligations under applicable laws and/or rules of professional conduct. BI
may disclose CONFIDENTIAL INFORMATION for corporate reporting purposes to its AFFILIATEs. 
 13.2 Each Party may disclose CONFIDENTIAL INFORMATION of
the other Party hereunder to the extent that such disclosure is reasonably necessary for prosecuting or defending litigation, complying with applicable government regulations, conducting preclinical or clinical trials or obtaining marketing approval
for the PRODUCT, provided that if a Party is required by law or regulation to make any such disclosure of the other Party’s CONFIDENTIAL INFORMATION it will, except where impracticable for necessary disclosures, for example in the event of
medical emergency, give reasonable advance notice to the other Party of such disclosure requirement and will use its best efforts assist such other Party to secure a protective order or confidential treatment of such CONFIDENTIAL INFORMATION
required to be disclosed. 
 13.3 Neither Party shall disclose CONFIDENTIAL INFORMATION of the other Party in any patent filings without the prior
written consent of such other Party. 
 13.4 The Parties agree that, except as may otherwise be required by applicable laws, regulations, rules, or
orders, including without limitation the rules and regulations promulgated by the US Securities and Exchange Commission, and except as may be authorised in Section 13.2, no material information concerning this AGREEMENT and the transactions
contemplated herein shall be made public by either Party without the prior written consent of the other. Each Party agrees that it shall cooperate fully and in a timely manner with the other with respect to all disclosures to the Securities and
Exchange Commission and any other governmental and regulatory agencies, including requests for confidential treatment of CONFIDENTIAL INFORMATION of either Party included in any such disclosure. 

13.5 The Parties expressly acknowledge and agree that any breach or threatened breach of Section 13 by either Party may cause immediate and
irreparable harm to the other Party that may not be adequately compensated by damages. Each Party therefore agrees that in the event of such breach or threatened breach by the receiving Party, and in addition to any remedies available at law, the
disclosing Party shall have the right to seek injunctive relief, without bond, in connection with such a breach or threatened breach. 
 13.6 This
confidentiality obligations of this Section 13 shall survive the termination or expiration of this AGREEMENT for period of [...***...], or, with respect to CONFIDENTIAL
INFORMATION of a THIRD PARTY, for such longer period as is required by the applicable agreement pursuant to which both Parties are bound with regards to the 

***Confidential Treatment Requested 

  
 Page 43 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 disclosing THIRD PARTY or with respect to any Confidential Information of GENENTECH disclosed to BI or its
Affiliates by or on behalf of HORIZON. 
 14. DURATION AND TERMINATION 

14.1 Duration 
 The AGREEMENT shall be effective as of the
EFFECTIVE DATE and, subject to Section 14.2, shall continue for an indefinite period or until such earlier date that the Agreement is earlier terminated for cause pursuant to Section 14.2. Each Party may terminate the AGREEMENT for
convenience by giving written notice (Textform) with a three (3) year notice period per the end of a calendar month. Notwithstanding Section 14.2, the earliest a notice
pursuant to this Section 14.1 may take effect is 30 June 2024. 
 14.2 Termination for Cause 

14.2.1 In the event that a Party materially breaches its obligations under this AGREEMENT (including without limitation a MATERIAL SUPPLY BREACH or a
late payment of more than thirty (30) days from its due date), the non-breaching Party may terminate this AGREEMENT for cause (aus wichtigem Grund) in writing (Textform) upon thirty (30) business days prior written notice
(Textform) to the breaching Party, unless the breaching Party cures such breach to the non-breaching Party’s reasonable satisfaction during said 30 day period, or initiates remedial steps reasonably acceptable to the non-breaching Party
to cure the breach within a resonable time frame, if such a breach cannot be cured within 30 days. Notwithstanding the preceding sentence, in the event that a Party materially breaches its obligations under this AGREEMENT more than two
(2) times in any consecutive twenty-four (24) month period, the non-breaching Party may terminate this AGREEMENT for cause (aus wichtigem Grund) with immediate effect without providing the breaching Party with an opportunity to cure
such breach, by giving the breaching Party written notice thereof (Textform). 
 14.2.2 Each Party may terminate this AGREEMENT with
immediate effect by notice in writing (Textform) to the other Party, for cause, if such other Party is adjudicated to be insolvent or files a petition in bankruptcy.  

14.2.3 HORIZON may terminate this AGREEMENT with immediate effect by notice in writing (Textform) if HORIZON should be prevented by the HEALTH
AUTHORITIES from distributing PRODUCT on the market for all indications. In such event, [...***...] for the following: (A) HORIZON shall either (at HORIZON’s discretion) (i) [...***...] in accordance with the then existing
[...***...] for [...***...] (in which case [...***...]) or (ii) [...***...] of the unit price of the PRODUCT then in effect for the PRODUCT forecasted in the then existing [...***...] for such [...***...];
and (B) [...***...] any non-cancellable costs incurred by BI for COMPONENTS which were purchased by BI at HORIZON’s request to the extent that HORIZON has not yet paid for such COMPONENTS; and (C) [...***...] 

***Confidential Treatment Requested 

  
 Page 44 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...]. Notwithstanding the foregoing,
[...***...] under this section in the event that such HEALTH AUTHORITY action is solely due to any breach of BI’s warranties under this AGREEMENT or any negligence or willful misconduct by BI. 

14.2.4 Either Party may terminate this AGREEMENT upon thirty (30) days written notice (Textform) to the other Party (or its successor) in the event
of a CHANGE OF CONTROL of the other Party (or in the case of HORIZON, of its AFFILIATES who have or have had a direct or indirect connection to this AGREEMENT or the QUALITY ASSURANCE AGREEMENT, or, in the case of BI, of its AFFILIATES who are
Permitted Subcontractors) which right of termination shall be exercised within five (5) months after the Party subject to a CHANGE OF CONTROL has informed the other Party of the CHANGE OF CONTROL event, provided that BIs’ rights of
termination hereunder shall be limited to a CHANGE OF CONTROL of HORIZON or its Affiliates with the new controlling entity being a a direct competitor to BI or its AFFILIATES in the field of contract manufacturing of biopharmaceuticals by means of
[...***...]. Each Party shall inform the other Party in writing (Textform) of a CHANGE OF CONTROL event which gives rise to a right of termination of the other Party pursuant to this Section at the latest within ten (10) Business
Days of the implementation of the CHANGE OF CONTROL event. 
 14.2.5 All payments in connection with early termination shall be due within [...***...]
after receipt by BI of the notice of early termination from HORIZON and receipt by HORIZON of the respective invoice from BI. 
 14.3 Effect of
Termination 
 14.3.1 In the event of any termination of this AGREEMENT (other than for BI’s material breach or negligence or willful misconduct by
BI), HORIZON shall also do one of the following (at HORIZON’s option): (i) HORIZON shall purchase (in which case BI shall sell) PRODUCT [...***...] or (ii) HORIZON shall pay to BI an amount equal to [...***...] of the unit
price of the PRODUCT then in effect for the PRODUCT [...***...]; provided, however, that with regard to any [...***...] by BI at the time of termination, [...***...] and (B) [...***...] for any non-cancellable costs
incurred by BI for COMPONENTS which were purchased by BI at HORIZON’s request to the extent that HORIZON has not yet paid for such COMPONENTS; and (C) [...***...]. Notwithstanding the foregoing, in the event of termination by HORIZON
under Section 14.2.3 (prevention by HEALTH AUTHORITIES), Section 14.2.3 shall govern and this Section 14.3.1 shall not apply. 

***Confidential Treatment Requested 

  
 Page 45 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 14.3.2 In the event of any termination or expiration of this AGREEMENT, at the request of HORIZON, BI shall
either (i) destroy all material, including but not limited to samples and all documentation received from HORIZON under this AGREEMENT, the CONSOLIDATED SUPPLY AGREEMENT, the ORIGINAL SUPPLY AGREEMENT or the RESTATED SUPPLY AGREEMENT, or
(ii) deliver the same to HORIZON or a party nominated by HORIZON, at HORIZON’s cost (except in the case of termination by HORIZON for BI’s material breach, in which case such destruction or delivery shall be at BI’s cost). 

14.3.3 BI shall promptly return all of HORIZON’s CONFIDENTIAL INFORMATION (as well as all CONFIDENTIAL INFORMATION of HORIZON provided to BI under the
ORIGINAL SUPPLY AGREEMENT, the RESTATED SUPPLY AGREEMENT or the CONSOLIDATED SUPPLY AGREEMENT) to HORIZON, except for a single copy and/or sample of each item for documentation purposes and for the purpose of compliance with the legal obligations
under applicable law only. BI’s responsibility to keep and store all other materials provided by HORIZON in the course of this AGREEMENT shall terminate [...***...] after
expiration or termination of this AGREEMENT (except as may be otherwise provided in the QUALITY ASSURANCE AGREEMENT with respect to storage of records and BATCH samples). 

14.3.4 HORIZON shall promptly return all of BI’s CONFIDENTIAL INFORMATION (as well as all CONFIDENTIAL INFORMATION of BI provided to HORIZON under the
ORIGINAL SUPPLY AGREEMENT, the RESTATED SUPPLY AGREEMENT or the CONSOLIDATED SUPPLY AGREEMENT) to BI, except for a single copy and/or sample for documentation purposes only. 

14.3.5 The following provisions shall survive termination of this AGREEMENT: Sections 4.3.6 (2nd paragraph
only), 4.4.4, 4.7.2, 6.3.8, 6.4, 8.1, 8.2, 8.3, 8.4, 8.5, 9, 10, 11, 12, 13, 14.2.3, 14.2.5, 14.3, 14.4 and 15. In addition, the applicable terms of the QUALITY ASSURANCE AGREEMENT with respect to the storage of records and BATCH samples for each
BATCH of DRUG SUBSTANCE and PRODUCT, or otherwise specified to survive termination, shall also survive the termination of this AGREEMENT. Termination of this AGREEMENT shall not relieve either Party of any liability which accrued hereunder prior to
the effective date of such termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this AGREEMENT, nor prejudice either Party’s right to obtain
performance of any obligation. 
  

	14.4	Technology Transfer 

 14.4.1 In connection with (i) the establishment of a second source
manufacturer pursuant to Section 4.9 or 4.10, or (ii) or any expiration or termination of this AGREEMENT, HORIZON shall be entitled to request TRANSFER SUPPORT and/or PROCESS PACKAGE (as defined in Section 2 and below, respectively),
as applicable, from BI. Upon receipt by BI of such written request from HORIZON, BI shall, as soon as practicable after such written request, and only to the extent necessary and for the sole purpose that an established manufacturer of
biopharmaceuticals at large scale (whether HORIZON or a THIRD PARTY designated by 
 ***Confidential Treatment Requested 

  
 Page 46 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 HORIZON) may manufacture DRUG SUBSTANCE or PRODUCT (it being understood that there may be separate such
manufacturers for DRUG SUBSTANCE and PRODUCT), 
  

	 	(i)	Provide reasonable support and assistance to HORIZON with [...***...] of the then current MANUFACTURING PROCESS of the DRUG SUBSTANCE and/or PRODUCT from
BI to HORIZON or such secondary source manufacturer during a period of [...***...] from HORIZON’s written notice of determination of such different second source manufacturer with a total capacity of [...***...] at an hourly rate of
[...***...] for upstream, downstream, quality control, quality assurance and analytics (the “TRANSFER SUPPORT”), and/ or 

  

	 	(ii)	deliver to HORIZON the PROCESS PACKAGE (as defined in Section 2) consisting of the most current version of the documentation and materials set forth below, always to the extent not already in HORIZON’s
possession: 

  

	 	A.	MASTER BATCH RECORD (including MASTER BATCH RECORDS for buffers, sampling plans); 

  

	 	B.	MANUFACTURER’S RELEASE SPECIFICATIONS; 

  

	 	C.	Analytical procedures for in-process control (IPC), release and stability, as applicable; 

  

	 	D.	Bill of materials and raw materials specifications; 

  

	 	E.	Storage specifications and instructions for DRUG SUBSTANCE and PRODUCT, as applicable, and other materials; 

  

	 	F.	Executed BATCH records (i.e. the filled-in MASTER BATCH RECORD) from the most recent three (3) BATCHES; 

  

	 	G.	Analytical records from the most recent three (3) BATCHES; 

  

	 	H.	Stability protocols and reports, as applicable; 

  

	 	I.	Process validation protocols and reports; 

  

	 	J.	Method validation protocols and reports; 

  

	 	K.	HORIZON material including but not limited to the reference standards, WCB, reagents, and retained DRUG SUBSTANCE and PRODUCT samples, as applicable, including in-process samples, and other than samples a or applicable
laws and regulations in the jurisdictions in which such retention of material occurs; and 

 ***Confidential Treatment
Requested 

  
 Page 47 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

	 	L.	Any other documents, data or materials that the Parties mutually agree are necessary or reasonably required for HORIZON and/ or its Affiliates or HORIZON’s designee(s) to manufacture DRUG SUBSTANCE and PRODUCT, as
applicable, using the MANUFACTURING PROCESS and support APPROVALS for the PRODUCT, which documents, data and materials may be reflected in a list to be mutually agreed by the Parties, with such agreement not to be unreasonably withheld, delayed or
conditioned. 

 (the TRANSFER SUPPORT under (i) and the PROCESS PACKAGE under (ii) shall collectively be referred to
as “TECHNOLOGY TRANSFER”). In the event, the PARTIES agree to additional transfer support activities, such services shall be covered in an additional CHANGE ORDER. 

HORIZON shall be solely responsible for any and all regulatory actions and other requirements, activities and actions required by HEALTH
AUTHORITIES and any other regulatory authorities or under applicable laws and all related regulatory costs and expenses that arise in conjunction with any TECHNOLOGY TRANSFER. 

14.4.2 Except in the event that HORIZON terminates this AGREEMENT for BI’s material breach as set forth in Section 14.2.1, HORIZON shall bear all
costs and expenses for any and all TECHNOLOGY TRANSFER. If HORIZON terminates this AGREEMENT for BI’s material breach, then BI shall bear all TRANSFER SUPPORT costs (which, for clarity, include all BI FTE and out of pocket costs incurred in the
delivery of the PROCESS PACKAGE). 
 15. MISCELLANEOUS 

15.1 Performance by Affiliates 
 The Parties recognize that
each Party may perform some or all of its obligations under this AGREEMENT through one or more of its AFFILIATES, provided, however, that each Party shall remain responsible for such performance by its AFFILIATES and shall cause its AFFILIATES to
comply with the provisions of this AGREEMENT in connection with such performance. Each Party hereby expressly waives any requirement that the other Party exhausts any right, power or remedy, or proceeds against an AFFILIATE, for any obligation or
performance hereunder prior to proceeding directly against such Party. 
 15.2 Force Majeure 

Neither Party shall be liable for any failure or delay in performance or non-performance caused by circumstances beyond the reasonable control of such Party,
including but not limited to explosion, fire, flood, labour strike or labour disturbances, sabotage, order or decree of any court or action of any governmental authority (except where such order, decree or action is a direct result of BI’s
breach of its obligations hereunder), or other causes, whether similar or dissimilar to those specified which cannot reasonably be controlled by the Party who failed to perform 

  
 Page 48 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 (each such event, a “FORCE MAJEURE EVENT”). A Party affected by a FORCE MAJEURE EVENT shall
give notice of such to the other Party as soon as is reasonably possible, and shall resume performance hereunder as soon as is reasonably possible. Each Party shall have the right to terminate this AGREEMENT in the event that a FORCE MAJEURE EVENT
continues for more than thirty (30) business days upon written notice thereof. 
 15.3 Assignment 

This AGREEMENT shall be binding upon the successors and assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of
its successors and assigns. Except as expressly provided for herein, neither this AGREEMENT nor any rights or obligations hereunder may be assigned by either Party without the other Party’s prior written consent (not to be unreasonably withheld
or delayed), except that either Party may (a) assign its rights and obligations under this Agreement to any of its AFFILIATES, or (b) assign this AGREEMENT in its entirety to its sucessor to all or substantially all of its business or
assets to which this AGREEMENT relates, unless such successor does not have the financial resources to perform such Party’s obligations under this AGREEMENT in the reasonable judgment of the other Party by submitting pertinent financial
information to such other Party. In the event of (b) above: (i) if HORIZON is the assignor, BI reserves the right to terminate this AGREEMENT upon one hundred eighty (180) days prior written notice in the event that such successor is
a direct competitor to BI in the field of contract manufacturing of biopharmaceuticals by means of [...***...]; and (ii) HORIZON reserves the right to terminate this AGREEMENT
upon one hundred eighty (180) days prior written notice in the event that such successor is a direct competitor to HORIZON in any indication for which PRODUCT is being marketed or sold. In case of an assignment, the assigning party shall
immidiately notify the other Party about the intended or executed assignment, as applicable, and the assignee. Any subsequent assignee or transferee shall be bound by the terms of this AGREEMENT. Any assignment of this AGREEMENT that is not in
conformance with this Section 15.3 shall be null, void and of no legal effect. 
 15.4 Notices 

Any notice required or permitted to be given hereunder by either Party shall be in writing and shall be (i) delivered personally, (ii) sent by
registered mail, return receipt requested, postage prepaid or (iii) delivered by facsimile and confirmed by certified or registered mail to the addresses or facsimile numbers set forth below: 

If to HORIZON: 
 Horizon
Pharma Ireland Limited 
 Connaught House 

1 Burlington Road, Dublin 4 

Ireland 
 Facsimile: +353 1 77
22 101 
 Attention: VP, Business Development 

Copy to: Legal Department 

***Confidential Treatment Requested 

  
 Page 49 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 If to BI: 

Boehringer Ingelheim Biopharmaceuticals GmbH 

Birkendorfer Straße 65 

88397 Biberach an der Riss 

Germany 
 Attention: Head of
B&C 
 Fax: +49/ 7351/54 - 4845 

Phone: +49/ 7351/54 - 96145 

With a copy to: 
 Boehringer
Ingelheim Biopharmaceuticals GmbH 
 Binger Straße 173 

55216 Ingelheim am Rhein 

Germany 
 Attention: Corporate
Legal 
 Fax: +49/ 6132 77-4080 

Phone: +49/ 6132 77-2106 
 15.5 Dispute
Resolution; Governing Law 
 15.5.1 In the event of any controversy or claim arising out of, relating to or in connection with any provision of this
AGREEMENT, or the rights or obligations of the Parties hereunder, the Parties first shall try to settle their differences amicably between themselves by referring the disputed matter to the Chief Executive Officer of HORIZON and the board of
management (Geschäftsführung) of BI for discussion and resolution. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Party, and within [...***...] of such notice the Chief Executive Officer of HORIZON and the board of management (Geschäftsführung) or one Managing Director (with proper authorization) of BI
shall meet for attempted resolution by good faith negotiations. If such personnel are unable to resolve such dispute within [...***...] of initiating such negotiations, the controversy or claim will be referred to binding arbitration as set
forth in Section 15.5.2. 
 15.5.2 Any controversy or claim arising out of, relating to or in connection with any provision of this AGREEMENT, or the
rights or obligations of the Parties hereunder, and not resolved by executive mediation in accordance with Section 15.5.1 hereof, shall be referred to and finally settled by binding arbitration, in accordance with the Rules of Arbitration of
the International Chamber of Commerce in force on the date the demand for arbitration is filed, which Rules are deemed to be incorporated by reference into this section. [...***...] 

***Confidential Treatment Requested 

  
 Page 50 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...]. The language to be used in the
arbitral proceedings shall be English. The place of arbitration shall be [...***...]. Any determination by such arbitration shall be final and conclusively binding. Judgment on the arbitral award may be entered in any court having jurisdiction
thereof. [...***...]. 
 15.5.3 This AGREEMENT shall be governed by and construed in accordance with the laws of Germany without reference to its
conflict of law rules. 
 15.5.4 The Parties expressly exclude the application of the United Nations Convention on Contracts for the International Sale of
Goods to this AGREEMENT. 
 15.5.5 This Section 15.5 shall also apply to quality disputes that cannot be resolved by the procedures set forth in the
QAA. 
 15.6 Independent Contractor 
 Each of the Parties
hereto is an independent contractor and nothing herein contained shall be deemed to constitute the relationship of partners or joint venturers, or of principal and agent between the Parties hereto. Neither Party shall have the authority to bind the
other Party. 
 15.7 Waiver 
 Any delay
in enforcing a Party’s rights under this AGREEMENT or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this AGREEMENT, excepting only
as to an express written and signed waiver as to a particular matter for a particular period of time. 
 15.8 Severability 

If any of the provisions of this AGREEMENT or parts thereof should be or become invalid, the remaining provisions will not be affected. The Parties shall
undertake to replace the invalid provision or parts thereof by a new provision which will approximate as closely as possible the intent of the Parties. 

15.9 Entire Agreement 
 This AGREEMENT, the QUALITY
ASSURANCE AGREEMENT, the TERMINATION AGREEMENT and the Exhibits set forth the entire agreement between the Parties, and supersede all previous agreements (including but not limited to the RESTATED SUPPLY AGREEMENT), negotiation and understanding,
written or oral, regarding the subject matter 
 ***Confidential Treatment Requested 

  
 Page 51 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 hereof, excluding, however the LYOPHILISATION DEVELOPMENT AGREEMENT. This AGREEMENT may be modified or
amended only by an instrument in writing duly executed on behalf of the Parties. For the avoidance of doubt, this AGREEMENT does not supersede the TERMINATION AGREEMENT entered into by the Parties on June 6, 2007. 

The Parties agree that the CONSOLIDATED SUPPLY AGREEMENT is hereby terminated as of the EFFECTIVE DATE and is superseded and replaced by this AGREEMENT. Such
termination does not affect any liability, right, remedy or obligation accrued under the CONSOLIDATED SUPPLY AGREEMENT prior to the EFFECTIVE DATE except to the extent expressly set forth in this AGREEMENT. 

15.10 Headings 
 The section headings appearing herein,
including those of the exhibits, are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this AGREEMENT. 

15.11 Interpretation 
 In this AGREEMENT, unless the
context otherwise requires 
  

	 	(a)	the the singular includes the plural and vice versa and references to one gender shall include all genders; 

  

	 	(b)	the words “includes”, “including” and “in particular” (or any similar term) are not to be construed as implying any limitation and shall be read and construed as if immediately followed by
the words “without limitation”; 

  

	 	(c)	the terms “Representation(s)”, “Warranty”, Warranties”, “represents” and “warrants” as set forth in this AGREEMENT shall have the meaning as set forth in Section 434 of
the German Civil Code (BGB) and shall not be interpreted as a guarantee under Sections 311, 443 or 633 of the German Civil Code (BGB) or any other provision of German law; 

 

	 	(d)	references to the recitals/preamble, Sections and Exhibits are to recitals/preamble, sections and exhibits of this AGREEMENT; and 

  

	 	(e)	the word “or” means “and/or”. 

 15.12 Priority of Documents 

In the event of a conflict or ambiguity between any term of the ASSET PURCHASE AGREEMENT, this AGREEMENT and its Exhibits and any purchase order or the like,
the following order of precedence shall apply (1= highest priority) except where explicitly provided otherwise. The document with the higher priority shall prevail over the document with the lower priority. 

  
 Page 52 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 1. The ASSET PURCHASE AGREEMENT, except for the event that a provision of this AGREEMENT expressly and
specifically states the intent to supersede a specific provision of the ASSET PURCHASE AGREEMENT 
 2. This AGREEMENT and its Exhibits 

4. The QAA and its Exhibits, except for the event that a provision of the QAA expressly and specifically states the intent to supersede a specific provision of
this AGREEMENT 
 5. Any purchase order or the like 
 15.13
Ambiguities 
 Ambiguities, if any, in this AGREEMENT shall not be strictly construed against either Party, regardless of which Party is deemed to have
drafted the provision at issue. 
 15.14 Counterparts 

The AGREEMENT may be executed in two or more counterparts, each of which shall be an original and all of which shall constitute the same document.F 

15.15 English Language 
 The English language will govern
any interpretation of or dispute in connection with this AGREEMENT. 
 [REMAINDER OF PAGE
IS INTENTIONALLY BLANK. 
 THE SIGNATURE
PAGE FOLLOWS.] 

  
 Page 53 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 In Witness Whereof, the Parties hereto have caused this AGREEMENT to be executed by their duly
authorized representatives as of the EFFECTIVE DATE. 
  

									
	Biberach an der Riss, Germany	 		 	Dublin, Ireland
			
	 BOEHRINGER INGELHEIM

BIOPHARMACEUTICALS GMBH
	 		 	HORIZON PHARMA IRELAND LIMITED
					
	By:	 	 /s/ Alois Konrad
	 		 	By:	 	 /s/ David G. Kelly

	Name:	 	Alois Konrad	 		 	Name:	 	David G. Kelly
	Title:	 	VP, Business & Contracts	 		 	Title:	 	Director
	Date:	 	June 29, 2017	 		 	Date:	 	June 29, 2017

  

			
	By:	 	 /s/ ppo. Andrea Stöckle

	Name:	 	Andrea Stöckle
	Title:	 	Head, Legal Biopharmaceuticals
	Date:	 	June 29, 2017

  
 Page 54 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 List of Exhibits: 

Exhibit 1: Product Specifications 
 Exhibit 2: Drug Substance
Specifications 
 Exhibit 3: Certificate of Analysis (COA) 

Exhibit 4: Certificate of Compliance (COC) 
 Exhibit 5: DNA
sequence of Interferon Gamma lb 
 Exhibit 6: Product 
 Exhibit
7 a, b and c: Manufacturing Processes for DRUG SUBSTANCE of Imukin, Actimmune and harmonised process thereof 
 Exhibit 8: Governance: Product Manager,
Product Team and Steering Committee 
 Exhibit 9: Billing plan for additional services 

Exhibit 10: Price 
 Exhibit 11: Rolling Forecast for Product 

Exhibit 12: Territory 
 Exhibit 13: Permitted Subcontractors 

Exhibit 14: Costs of Regulatory Inspections for PRODUCT 
 Exhibit
15: BCP 
 Exhibit 16: Manufacturing Process for PRODUCT of Imukin, Actimmune and harmonised process thereof 

Exhibit 17: Additional Scope of Services for Process Harmonisation 

  
 Page 55 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 Exhibit 1: Product Specifications 

[...***...] 

***Confidential Treatment Requested 

  
 Page 56 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...]

 ***Confidential Treatment Requested 
  

  
 Page 57 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 58 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 59 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 Exhibit 2: Drug Substance Specifications 

[...***...] 

***Confidential Treatment Requested 

  
 Page 60 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 
  

  
 Page 61 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 62 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 63 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 3: Certificate of Analysis (COA): 

[...***...] 

***Confidential Treatment Requested 

  
 Page 64 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 4: Certificate of Compliance (COC) 

[...***...] 

***Confidential Treatment Requested 

  
 Page 65 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 5: DNA sequence of Interferon Gamma lb 

[...***...] 

***Confidential Treatment Requested 

  
 Page 66 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 6: PRODUCT 

[...***...] 

***Confidential Treatment Requested 

  
 Page 67 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 7 a, b and c: MANUFACTURING PROCESSES 

[...***...] 

***Confidential Treatment Requested 

  
 Page 68 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 7 a: MANUFACTURING PROCESS for ACTIMMUNE: 

[...***...] 

***Confidential Treatment Requested 
  

  
 Page 69 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 70 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 71 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 72 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 73 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 7 b: MANUFACTURING PROCESS for IMUKIN PRODUCT: 

[...***...] 
 ***Confidential
Treatment Requested 

  
 Page 74 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 75 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 76 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 77 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 78 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 7 c: Harmonised MANUFACTURING PROCESS for ACTIMMUNE and IMUKIN PRODUCT [...***...]: 
 [...***...] 

***Confidential Treatment Requested 

  
 Page 79 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 80 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 81 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 82 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 83 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 8: Governance 

[...***...] 
 ***Confidential
Treatment Requested 
  

  
 Page 84 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 9: Billing plan for additional services 

  
 Page 85 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 86 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 87 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 10: Price 

[...***...] 

***Confidential Treatment Requested 

  
 Page 88 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 89 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 90 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 11: Rolling Forecast for DP 

[...***...] 

***Confidential Treatment Requested 

  
 Page 91 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 92 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 12: Territory 

[...***...] 

***Confidential Treatment Requested 

  
 Page 93 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 13: Permitted subcontractors 

[...***...] 

***Confidential Treatment Requested 

  
 Page 94 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 14: Costs of Regulatory Inspections for Product 

[...***...] 

***Confidential Treatment Requested 

  
 Page 95 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 Exhibit 15: Generic Business Continuity Plan (BCP) 

[...***...] 

***Confidential Treatment Requested 

  
 Page 96 of 138 

					
		  	Confidential	  	CorA-No.: 82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 97 of 138 

					
		  	Confidential	  	CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 98 of 138 

					
		  	Confidential	  	CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 99 of 138 

					
		  	Confidential	  	CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 100 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 101 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 102 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 
  

  
 Page 103 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 Exhibit 16: Manufacturing Process for PRODUCT of Imukin, Actimmune and harmonised process thereof 

[...***...] 

***Confidential Treatment Requested 

  
 Page 104 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 Exhibit 17: Additional Scope of Services for Process Harmonization 

[...***...] 

***Confidential Treatment Requested 

  
 Page 105 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 106 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 107 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 
  

  
 Page 108 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 109 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 110 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 111 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 112 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 113 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 114 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 
  

  
 Page 115 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 116 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 117 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 118 of 138 

					
		  	Confidential	  	 CorA-No.:82795

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 119 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 120 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 121 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 122 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 123 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 124 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 125 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 126 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 127 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 128 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 129 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 130 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 131 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

  
 Page 132 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 133 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 134 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 135 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 136 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 137 of 138 

					
		  	CONFIDENTIAL	  	CorA: 151373

  

 [...***...] 

***Confidential Treatment Requested 

  
 Page 138 of 138

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]